

Accepted Manuscript

International consensus: what else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritis, systemic sclerosis, systemic lupus erythematosus, antiphospholipid syndrome and Sjogren's syndrome)?

Roberto Giacomelli, Antonella Afeltra, Alessia Alunno, Chiara Baldini, Elena Bartoloni-Bocci, Onorina Berardicurti, Francesco Carubbi, Alberto Cauli, Ricard Cervera, Francesco Ciccia, Paola Cipriani, Fabrizio Conti, Salvatore De Vita, Paola Di Benedetto, Andrea Doria, Alexandros A. Drosos, Ennio Giulio Favalli, Saviana Gandolfo, Mariele Gatto, Rosa Daniela Grembiale, Vasiliki Liakouli, Rik Lories, Ennio Lubrano, Claudio Lunardi, Domenico Paolo Emanuele Margiotta, Laura Massaro, Pierluigi Meroni, Antonia Minniti, Luca Navarini, Monica Pendolino, Federico Perosa, Jacques-Olivier Pers, Marcella Prete, Roberta Priori, Francesco Puppo, Luca Quartuccio, Amelia Ruffatti, Piero Ruscitti, Barbara Russo, Piercarlo Sarzi-Puttini, Yehuda Shoenfeld, George A. Somarakis, Francesca Romana Spinelli, Elisa Tinazzi, Giovanni Triolo, Francesco Ursini, Gabriele Valentini, Guido Valesini, Serena Vettori, Claudio Vitali, Athanasios G. Tzioufas

PII: S1568-9972(17)30183-0
DOI: doi:[10.1016/j.autrev.2017.07.012](https://doi.org/10.1016/j.autrev.2017.07.012)
Reference: AUTREV 2041

To appear in: *Autoimmunity Reviews*

Received date: 15 May 2017
Accepted date: 20 May 2017

Please cite this article as: Giacomelli Roberto, Afeltra Antonella, Alunno Alessia, Baldini Chiara, Bartoloni-Bocci Elena, Berardicurti Onorina, Carubbi Francesco, Cauli Alberto, Cervera Ricard, Ciccia Francesco, Cipriani Paola, Conti Fabrizio, De Vita Salvatore, Di Benedetto Paola, Doria Andrea, Drosos Alexandros A., Favalli Ennio Giulio, Gandolfo Saviana, Gatto Mariele, Grembiale Rosa Daniela, Liakouli Vasiliki, Lories Rik, Lubrano Ennio, Lunardi Claudio, Margiotta Domenico Paolo Emanuele, Massaro Laura, Meroni Pierluigi, Minniti Antonia, Navarini Luca, Pendolino Monica, Perosa Federico, Pers Jacques-Olivier, Prete Marcella, Priori Roberta, Puppo Francesco, Quartuccio Luca, Ruffatti Amelia, Ruscitti Piero, Russo Barbara, Sarzi-Puttini Piercarlo, Shoenfeld Yehuda, Somarakis George A., Spinelli Francesca Romana, Tinazzi Elisa, Triolo Giovanni, Ursini Francesco, Valentini Gabriele, Valesini Guido, Vettori Serena, Vitali Claudio, Tzioufas Athanasios G., International consensus: what else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritis, systemic sclerosis, systemic lupus erythematosus, antiphospholipid syndrome and Sjogren's syndrome)?, *Autoimmunity Reviews* (2017), doi:[10.1016/j.autrev.2017.07.012](https://doi.org/10.1016/j.autrev.2017.07.012)



International consensus: what else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritis, systemic sclerosis, systemic lupus erythematosus, antiphospholipid syndrome and Sjogren's syndrome)?

Subtitle

The unmet needs and the clinical grey zone in autoimmune disease management.

Authors

*¹Roberto Giacomelli, ²Antonella Afeltra, ³Alessia Alunno, ⁴Chiara Baldini, ³Elena Bartoloni-Bocci, ¹Onorina Berardicurti, ¹Francesco Carubbi, ⁵Alberto Cauli, ⁶Ricard Cervera, ⁷Francesco Ciccia, ¹Paola Cipriani, ⁸Fabrizio Conti, ⁹Salvatore De Vita, ¹Paola Di Benedetto, ¹⁰Andrea Doria, ¹¹Alexandros A. Drosos, ¹²Ennio Giulio Favalli, ⁹Saviana Gandolfo, ¹⁰Mariele Gatto, ¹³Rosa Daniela Grembiale, ¹Vasiliki Liakouli, ¹⁴Rik Lories, ¹⁵Ennio Lubrano, ¹⁶Claudio Lunardi, ²Domenico Paolo Emanuele Margiotta, ⁸Laura Massaro, ¹²Pierluigi Meroni, ⁸Antonia Minniti, ²Luca Navarini, ⁸Monica Pendolino, ¹⁷Federico Perosa, ¹⁸Jacques-Olivier Pers, ¹⁷Marcella Prete, ⁸Roberta Priori, ¹⁹Francesco Puppo, ⁹Luca Quartuccio, ¹⁰Amelia Ruffatti, ¹Piero Ruscitti, ²⁰Barbara Russo, ²¹Piercarlo Sarzi-Puttini, ²²Yehuda Shoenfeld, ¹¹George A. Somarakis, ⁸Francesca Romana Spinelli, ¹⁶Elisa Tinazzi, ⁷Giovanni Triolo, ¹³Francesco Ursini, ²⁰Gabriele Valentini, ⁸Guido Valesini, ²⁰Serena Vettori, ²³Claudio Vitali, ²⁴Athanasios G. Tzioufas

Affiliation

¹Division of Rheumatology, Department of Biotechnological and Applied Clinical Science, University of L'Aquila, L'Aquila, Italy;

²Clinical Medicine and Rheumatology Department, Campus Bio-Medico University of Rome, Rome, Italy;

³Rheumatology Unit, Department of Medicine, University of Perugia, Perugia, Italy;

⁴Rheumatology Unit, University of Pisa, Via Roma, Pisa, Italy;

⁵Chair of Rheumatology and Rheumatology Unit, University Clinic AOU of Cagliari, Italy;

⁶Department of Autoimmune Diseases, Hospital Clínic, Barcelona, Catalonia, Spain;

⁷Rheumatology Unit, Department of Internal Medicine, University of Palermo, Palermo, Italy

⁸Rheumatology Unit, Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Rome, Italy;

⁹Rheumatology Clinic, Department of Medical and Biological Sciences, Azienda Ospedaliero-Universitaria 'S. Maria della Misericordia', Udine, Italy;

¹⁰Division of Rheumatology, department of Medicine, University of Padova, Padova, Italy;

¹¹Rheumatology Clinic, Department of Internal Medicine Medical School, University of Ioannina, Ioannina, Greece;

¹²Division of Rheumatology, ASST.G Pini; Department of Clinical Sciences and Community Health, University of Milan and Istituto Auxologico Italiano, Milan, Italy;

¹³Departement of health sciences, University of Catanzaro "Magna Graecia", Catanzaro Italy;

¹⁴Laboratory of Tissue Homeostasis and Disease, Department of Development and Regeneration, KU Leuven and Division of Rheumatology , Skeletal Biology and Engineering Research Center, University Hospitals Leuven , Leuven , Belgium;

¹⁵Rheumatology Unit, Department of Medicine and Health Science "Vincenzo Tiberio", University of Molise, Campobasso, Italy;

¹⁶Department of Medicine, University of Verona, Verona, Italy;

¹⁷Department of Biomedical Sciences and Human Oncology (DIMO), Systemic Rheumatic and Autoimmune Diseases Unit, University of Bari Medical School, Bari;

¹⁸Immunology and Pathology, Brest University, SFR ScinBios, Labex 'Immunotherapy, Graft, Oncology', Brest, France;

¹⁹Department of Internal Medicine, Scleroderma Unit, Clinical Immunology Unit, University of Genova, Genova, Italy;

²⁰Rheumatology Section, Department of Clinical and Experimental Medicine, Second University of Naples, Naples, Italy;

²¹Rheumatology Unit, ASST-Fatebenefratelli-L , Sacco University Hospital, Milan , Italy;

²²The Zabłudowicz Center for Autoimmune Diseases, Sheba Medical Center, 5265601, Tel-Hashomer, Israel;

²³Sections of Rheumatology , Istituto San Giuseppe, Como and Casa di Cura di Lecco , Lecco , Italy;

²⁴Department of Pathophysiology, University of Athens, Athens, Greece.

Corresponding author

*Prof. Roberto Giacomelli MD PhD, Department of Biotechnological and Applied Clinical Science, Rheumatology Unit, School of Medicine, University of L'Aquila, Delta 6 Building, Via dell'Ospedale, 67100, L'Aquila, Italy, +390862434742, +390862433523, roberto.giacomelli@cc.univaq.it.

Abstract

Autoimmune diseases are a complex set of diseases characterized by immune system activation and, although many progresses have been done in the last 15 years, several unmet needs in the management of these patients may be still identified.

Recently, a panel of international Experts, divided in different working groups according to their clinical and scientific expertise, were asked to identify, debate and formulate a list of key unmet needs within the field of rheumatology, serving as a roadmap for research as well as support for clinicians. After a systematic review of the literature, the results and the discussions from each working group were summarised in different statements. Due to the differences among the diseases and their heterogeneity, a large number of statements was produced and voted by the Experts to reach a consensus in a plenary session. At all the steps of this process, including the initial discussions by the steering committee, the identification of the unmet needs, the expansion of the working group and finally the development of statements, a large agreement was attained.

This work confirmed that several unmet needs may be identified and despite the development of new therapeutic strategies as well as a better understanding of the effects of existing therapies, many open questions still remain in this field, suggesting a research agenda for the future and specific clinical suggestions which may allow physicians to better manage those clinical conditions still lacking of scientific clarity.

Key words

Unmet needs; rheumatoid arthritis; spondyloarthritides; systemic sclerosis; systemic lupus erythematosus; antiphospholipid syndrome; Sjogren's syndrome; biologic drugs treatment; remission; effectiveness.

Introduction

Autoimmune rheumatologic diseases, pathogenic conditions arising from an abnormal immune response, have been increasingly recognized over the past hundreds of years. The possible causes are not fully understood and both cellular and molecular mechanisms are involved [1,2]. Recently, insights into genetic susceptibility show that environmental triggers may be involved, acting via cellular pathways containing disease-associated polymorphisms. The target tissue provides a decisive microenvironment that affects immune-cell differentiation, leading to a chronic activation of immune system and, thus, development of the autoimmune disease [3,4].

New treatments have been introduced to target different inflammatory pathways and autoimmune rheumatologic diseases. The development of drugs for the treatment of these diseases parallels the increased knowledge of the pathogenic mechanisms. Current treatment guidelines suggest that early diagnosis and initial treatment with immunosuppressive drugs are necessary to limit damage and functional loss and to reduce mortality associated with autoimmune rheumatic disease [5-7]. In this context, it has been shown that frequently the disease course of affected patients is unpredictable as well as their responses, to standard treatments, are variable. Furthermore, it must be pointed out that in many conditions no validated biomarkers exist to predict the course of disease nor the response to therapy.

Thus, despite of recent advances both in diagnosis and treatment of rheumatic diseases, clinical remission in our patients cannot be reached in at least 50% of the treated patients and definite criteria to tailor the optimal therapy for any patients are still far away to be identified.

On these bases, an experts meeting was organized in Italy aimed to identify some relevant topics, still waiting for definitive conclusions in 6 different clinical conditions, and successively, after a systematic review of the literature, pointed out the level of knowledge for each previously identified unmet needs. The results and the conclusions of this work may allow physicians to better manage those challenges represented by the clinical conditions still lacking of scientific clarity.

Methods

The methodology consisted of a different steps process. In a first step, the organizers invited leading National and International Experts, defined on the basis of their citation frequency in the field and previous contributions to similar activities. This committee discussed the unmet needs in the management and in the potential treatment targets of autoimmune rheumatic diseases. In the course of this discussion there was unanimous agreement that defining therapeutic targets and an appropriate strategic treatment approach in autoimmune diseases would be valuable, but that evidence for its validity are still lacking. Thus, it was decided to perform a systematic review of literature (SLR), from 1th January 2000 until 31th July 2015, and search terms were formulated following the Appraisal of Guidelines for Research and Evaluation recommendations [8]. The strength of the selected evidence provided by an individual study depends on the ability of the study design to minimise the possibility of bias and to maximise attribution. The hierarchy of study types was indicated by levels of evidence suggested by Oxford University (<http://www.cebm.net/oxford-centre-evidence-based-medicine-levels-evidence-march-2009/>). At a subsequent meeting in October 2015 an expanded task force with increased international participation discussed the results of SLR. These invitations were a consequence of the individuals' contributions to the specific fields included in the topics of the meeting as well as deliberations among members of the steering committee. The discussions took place in separate breakout sessions, devoted to the different topics, and provisional sets of statements were developed. Each group was assigned a "leader" and "rapporteur" in charge of facilitating the discussion and communicating their findings to the conference on the last day in session. During this session, results from each group were summarised, presented, and further input was obtained from the congress. In fact, during the plenary session, certain items were reformulated and reordered and each statement, which was formulated as a draft for voting, in the course of the breakout sessions and by the whole task force, was subjected to voting as 'yes' (agreement with the wording) or 'no' (disagreement). Statements supported by $\geq 66\%$ of votes were accepted while the others were rejected outright. After the face-to-face meeting, the statements were distributed to the committee members by email for final comments. Only suggestions for improvements of clarity of wording or addressing redundancies were considered, while any change to the meaning was not accepted.

Results

Rheumatoid Arthritis Working Group

The disease course of Rheumatoid Arthritis (RA) is unpredictable, and despite of different biologic treatments, the complete inhibition of radiographic progression occurs in only half of patients, and about half of patients discontinue treatment within 5 years, independent of the therapeutic strategy employed. No biomarkers currently exist to predict the course of disease [9,10]. On these bases, 13 statements were formulated and voted.

The use of biologic drugs in RA: efficacy, time to response and drug survival

Based on direct and indirect comparative studies, no significant differences according to ACR response criteria, functional status, and radiographic progression exist among available biological drugs combined with methotrexate (MTX) in both MTX-naïve and MTX-insufficient responder patients. Level of Evidence (LoE) 1a, Grade of Recommendations (GoR) A

The only available direct comparison between 2 biological drugs in association with MTX for the treatment of RA has been provided by the 2-year AMPLE trial, demonstrating a similar clinical and radiographic response between abatacept and adalimumab [11]. Several meta-analyses of randomised controlled trials (RCTs) conducted with biologic agents in both MTX-naïve and insufficient responder populations similarly showed no significant difference among available biotherapies in terms of clinical response functional status, and radiographic progression [12-18].

The kinetics of response of subcutaneous abatacept and adalimumab are comparable. LoE 1b, GoR A

In the AMPLE trial, subcutaneous abatacept and adalimumab have been head-to-head compared in a MTX insufficient responder RA population. No significant differences were found in the kinetics of clinical response according to ACR20, 50 and 70 criteria between the 2 drugs [11].

No significant differences in time to response among other biological drugs may be assessed. LoE 5, GoR D

The comparative analysis of clinical response kinetics between two or more biological drugs may be performed only by head-to-head designed RCTs. With the only exception of the AMPLE trial [11], no head-to-head RCT comparing biologic agents in association with MTX have been performed yet. Moreover, real-life data from observational studies about this topic are still lacking.

Based on data coming from main international registries, the long-term drug persistence of etanercept seems to be higher when compared with monoclonal antibodies (adalimumab and infliximab). LoE 2b, GoR B

Drug retention may be considered a reliable indicator of overall treatment effectiveness in observational registries, as determined by both drug efficacy and safety profile. Thus, many studies from European and US biologic drug registries have provided data about long-term drug retention of tumor necrosis factors inhibitors (TNFi) drugs (especially etanercept, infliximab, and adalimumab) in RA. The majority of those real-life data showed a better retention rate of etanercept compared with monoclonal antibodies, especially in terms of long-term drug survival [19-25].

No significant differences in long-term drug retention among other biological drugs may be assessed. LoE 5, GoR D

Data on drug survival of biological agents other than TNFi coming from observational registries are still limited. The retention rates for abatacept and tocilizumab seems to be similar to what reported for etanercept, but to date a direct comparison has not been performed [26-28].

Biologic drugs in MTX intolerant patients: how effective is monotherapy?

Tocilizumab as monotherapy can be used with a similar efficacy to combination therapy for patients intolerant to MTX. LoE 1b, GoR A

The ACT-RAY study evaluated 2 different tocilizumab treatment strategies on 556 RA patients. Despite previously MTX treatment, they were randomized either to continue MTX with the addition of tocilizumab or switched to tocilizumab monotherapy. No clinically relevant superiority of the tocilizumab+MTX add-on strategy over the switch to tocilizumab monotherapy strategy was observed in DAS28-erythrocyte sedimentation rate (ESR) remission rate at week 24 [29].

Tocilizumab monotherapy demonstrated superiority over adalimumab monotherapy in reducing signs and symptoms of RA in MTX-intolerant patients, or in whom MTX was considered ineffective or inappropriate. No comparative data against tocilizumab are available for others TNF inhibitors. LoE 1b, GoR A

Gabay et al. compared the efficacy and safety of tocilizumab monotherapy and adalimumab monotherapy, in 452 RA patients. A significantly greater DAS28-ESR reduction was observed in patients treated with tocilizumab monotherapy when compared with adalimumab monotherapy, for whom MTX was deemed inappropriate [30].

The use of biologic drugs in rheumatoid extra-articular manifestations

Although a worsening of interstitial lung disease has been reported in RA patients treated with biologic drugs, the role of biological therapy is still unclear. LoE 5, GoR D

Although interstitial lung disease (ILD) is relatively rare in RA, some papers reported increased pulmonary toxicity induced by the biologics and especially the TNFi [31,32]. The drug-induced ILD may be carefully evaluated in patients with pre-existing pulmonary disease requiring biologics [31,32].

Golimumab, infliximab, and especially tocilizumab have been proven to significantly improve anemia, whereas no data are available for other biologic drugs. LoE 1b, GoR B

It has been shown that approximately 20% of RA patients may present anaemia. The analyses reported that golimumab, infliximab and tocilizumab may be able to improve haemoglobin levels in RA patients with inflammation inducing anaemia. Furthermore, tocilizumab may be more effective than TNFi for improving anaemia and normalizing iron metabolism in RA patients by inhibiting hepcidin production [33-37].

Vasculitis may be effectively treated with rituximab, whereas no data are available for other biologics. Data from the literature do not show consistent evidence of possible therapeutic effects of biologics on other extra-articular manifestations of RA. LoE 4, GoR C

Rituximab showed efficacy in rheumatoid vasculitis, that typically affects longstanding seropositive RA patients. A complete vasculitis remission may be observed after 6 months, associated with a

lowering of dose of steroids. Further courses of rituximab, may be effective in patients experienced a relapse [38].

Dose adjustments and discontinuation of biologic drugs in patients experiencing clinical remission

In RA patients treated with biologic agents, a possible strategy for maintaining clinical remission and/or low disease activity could be the dose tapering or increasing administration intervals. LoE 1b, GoR A

Although maintenance of low disease activity states is better with biologic agents continuation, there is some evidence for biologic agents dose reduction without loss of efficacy. In the majority of patients with stable low DAS28 and stable treatment, biologic agents can be down-titrated, which results in a possible reduction in costs [12,39,40].

May biomarkers be predictive of better effectiveness of biological drugs for RA?

Data on genetic, serological, and synovial biomarkers are still controversial and not useful to personalize RA treatment. LoE 5, GoR D

The use of biomarkers in RA may help in identifying disease risk, improving diagnosis and prognosis and assessing the response to treatment [41,42].

Some predictors are consistently predictive while several others are promising but await replication. Nevertheless, these biomarkers still require rigorous validation and have yet to make their way into clinical practice and therapeutic development. The challenge now is to design studies to validate all explored and promising findings individually and in combination to make these biomarkers relevant to clinical practice. Before that, no clinically useful baseline biomarkers can be used in individually tailored biologic treatment in RA [43].

The positivity of rheumatoid factor (RF) and/or anti-citrullinated protein antibody (ACPA) could be useful to drive the choice to rituximab. LoE 2, GoR C

Data coming from International registries and systematic reviews and meta-analyses support the role of RF and ACPA in driving the choice of B-cell depleting therapy with rituximab in RA, as second-line treatment after failure of the first biologic agent. However, ad hoc studies are lacking, thus strategy based on autoantibody profile still needs to be validated in RA [44-47].

Spondyloarthritides Working Group

The spondyloarthritides (SpA) include ankylosing spondylitis (AS), reactive arthritis, psoriatic arthritis (PsA), inflammatory bowel disease-associated spondyloarthropathy, and undifferentiated spondyloarthropathy [48,49]. Classification criteria for axSpA have been recently developed [48,49]. By using these criteria, patients may be classified as non-radiographic axial SpA (nr-axSpA), radiographic axial (ax)SpA or AS. Although biologic therapies showed a strong effect on the clinical outcome of these patients still less is known about their impact on radiographic progression and damage. On these bases, 10 statements were formulated and voted.

Does still exist a place for NSAIDs and Sulfasalazine in the treatment of SpA?

Continuous NSAIDs treatment might be efficacy on slowing radiographic progression in the spine of AS patients. LoE 1a, GoR A

Non-steroidal anti-inflammatory drugs (NSAIDs), are recommended as first-line drug treatment for AS patients. Continuous treatment with NSAIDs is preferred for patients with persistently active, symptomatic disease. Recently, a meta-analysis of randomized control trials showed that continuous NSAIDs treatment, rather than on-demand use, may be effective in retarding radiographic progression, especially in certain subgroups of patients, such as patients with high C reactive protein (CRP). Nevertheless, cardiovascular, gastrointestinal and renal risks should be taken into account when prescribing NSAIDs in these patients [53].

Continuous NSAIDs treatment seems to be not efficacy on slowing radiographic progression in the spine of nrAxSpA. LoE 3b, GoR B

Although NSAIDs treatment may be associated with retarded radiographic spinal progression in AS, this effect is less evident in nrAxSpA. In this subset, the positive effect on radiographic

progression may be lost due to the relatively low progression rate, in this subgroup. Furthermore, in this group, is still not clarify if the pathogenic damage may be oriented toward erosion more than new bone formation [54].

Sulfasalazine might be efficacy in slowing sacroiliac radiographic progression in patients with nrAxSpA but not in AS. LoE 2b, GoR B

Sulfasalazine (SSZ) has been used as a second-line approach for SpA patients refractory or intolerant to NSAIDs. The evidence supporting a role for this drug in AS is still controversial. However, SSZ seems to slow sacroiliac radiographic progression in nrAxSpa in which a reduction of radiographic progression has been pointed out [55,56].

The use of biologic drugs in SpA: clinical efficacy, radiographic progression and predictors of response

TNFi might be efficacy in slowing radiographic progression in patients with AS. Loe 3b, GoR B

Although patients with prevalent radiographic damage are prone to develop a more severe disease over time, there is some evidence that TNFi treatment might decelerate the radiographic progression [57-61].

TNFi might be efficacy in slowing radiographic progression in patients with nrAxSpA. LoE 3b, GoR B

In a monocentric study, patients with active nr-axSpA were treated with adalimumab for 24 months. Adalimumab improved the radiological outcomes, via the assessment of the radiograph of the spine and sacroiliac joints and magnetic resonance of the sacroiliac joints, after 2-years of follow-up [62].

TNFi showed efficacy in reducing disease activity in both AS and nrAxSpA, without significant differences between the different molecules. LoE 1a, GoR A

The introduction of TNFi marked a turning point in the management of SpA. Different meta-analyses showed that the different TNFi may significantly improve the disease activity for both AS

and nr-axSpA patients, when compared with placebo. No difference among the different molecules were pointed out [63-65].

Infliximab biosimilar is equivalent to infliximab in terms of efficacy. No data are available on slowing disease progression. LoE 1b, GoR A

In September 2013, the first biosimilar therapy (CT-P13) was licensed in the EU for the treatment of AS, after the results of the PLANETAS study [66]. Recently, a meta-analysis of available RCTs, to compare the efficacy and safety of infliximab-biosimilar with other biological drugs for the treatment of AS, was performed. This meta-analysis showed no significant difference in the efficacy of infliximab-biosimilar and other TNFi in terms of ASAS20 improvement. No data are available on slowing disease progression [67].

ESR, CRP, Ankylosing Spondylitis Disease Activity Score (ASDAS) and male gender are independent baseline predictors of response and/or continuation of TNFi. LoE 2b, GoR B

In the Groningen Leeuwarden Ankylosing Spondylitis (GLAS) study, an ongoing prospective longitudinal observational cohort study with follow-up visits according to a fixed protocol, AS naive patients starting infliximab, etanercept or adalimumab were included. Male gender, higher inflammatory markers, both ESR and CRP, higher ASDAS score, were identified as independent baseline predictors of response and/or continuation of TNFi. In contrast, higher baseline BASDAI score was independently associated with treatment discontinuation [68].

Clinical remission in SpA: is it possible to modify or discontinue biologic drugs?

Discontinuation of pharmacologic treatments might be tried in AS patients but high frequency of relapse is predictable (50% in 6 months, 70 % in 1 year, 100% in 3 years). LoE 2b, GoR B

In the study of Baraliakos X et al, AS patients received infliximab for 3 years. At the end of the study patients had the opportunity to continue or not the treatment. The discontinuation of long-term therapy with infliximab in patients with AS leads to a clinical relapse of the disease, with deterioration of signs and symptoms. Patients in partial remission or with low disease activity had a longer duration of benefit after discontinuation than patients with higher disease activity [69].

A tailored approach to reduce doses of TNFi seems to produce similar clinical outcomes at 1 year in AS patients. LoE 3b, GoR B

Different studies have evaluated the effectiveness of standard versus individually tailored reduced dosages of TNFi in AS patients, achieving low-disease activity. Dose reduction, in these studies, was patient-tailored (step-by-step approach) and consisted of lowering the dose and/or extending the intervals between doses. No difference was observed in the disease activity scores, between the group reducing the dosage and the standard dosage group, at 1 year of follow up [70,71].

Systemic sclerosis working group

Systemic Sclerosis (SSc) is characterized by immunological alterations, vasculopathy and fibrosis. Despite of several progress both in the knowledge of pathogenic steps and in the therapeutic options, when SSc is compared with other rheumatic conditions, it shows the lowest life expectancy rate [72]. The definite statements are not aimed to cover all the possible unmet needs to be addressed in SSc patients but underlying the aspects that unlike pulmonary hypertension are not usually covered in this field. On these bases, 6 statements were formulated and voted.

Is it possible to increase the overall survival of SSc patients?

Hematopoietic stem cell transplantation (HSCT) has been found to prolong survival in one controlled study. Mycophenolate has been reported to prolong survival in a retrospective cohort study. LoE 2, GoR B

Autologous HSCT resulted in a higher survival rate compared to intravenous pulse cyclophosphamide [73]. Nonetheless, the high HSCT treatment-related mortality (16.5%) during the first year after treatment make this approach restricted to some selected cases. In a retrospective single-centre cohort study, which included 172 patients with SSc, mycophenolate, given for more than 1 year, significantly increased the 5-years survival rate as compared to azathioprine, anti-thymocyte globulin, intravenous or oral cyclophosphamide and MTX [74].

*Challenges in SSc management, treatments of specific clinical features***No drug has been consistently found to prevent or treat myocardial fibrosis. LoE 4, GoR C**

Vasodilatory drugs, such as calcium channel blockers (CCBs) and angiotensin converting enzyme inhibitors (ACEinh) improve myocardial perfusion and ~~on~~ myocardial contractility in short term trials. Moreover, CCBs and ACEinh have been reported to be associated with a preserved left ventricular systolic function and diastolic function, respectively [75,76]. No drug or combination of drugs have been found to affect myocardial disease other than myocarditis.

Mycophenolate, rituximab and imatinib have been reported to be effective in SSc-ILD unresponsive to cyclophosphamide in prospective uncontrolled studies. LoE 3, GoR C

Cyclophosphamide is the only immunosuppressive agent that has shown to be effective, for the treatment of SSc-related ILD, in a randomized, controlled trial [77]. Mycophenolate, rituximab and imatinib have been reported to be effective in SSc-ILD, unresponsive to cyclophosphamide in prospective uncontrolled studies [78].

The proposed treatments for gut fibrosis have only a symptomatic effect. LoE 4, GoR D

Two main unmet needs can be identified in this topic: 1) the lack of appropriate outcome measures to validate each considered symptom; 2) the lack of clinical trials with an adequate patients size. Furthermore, although the majority of symptoms are related to a fibrotic involvement of the gastrointestinal tract, there is no evidence for anti-fibrotic effects of the currently available drugs. Therefore the proposed treatments have only a symptomatic effect [79].

MTX and biological drugs have been found to be effective on arthritis in uncontrolled studies. LoE 3, GoR D

Current treatment strategies for SSc-related inflammatory joint disease have not been evaluated in randomized controlled trials and generally derive from RA studies. Nevertheless, MTX and biological drugs have been found to be effective in SSc associated arthritis in uncontrolled studies [80].

No drug or therapy has been consistently found to affect disfiguring skin disease LoE 5, GoR D

Conventional therapy of telangiectasia is based on local light treatment based on pulsed dye laser (PDL) and/or intense pulsed light (IPL). PDL was effective in treating telangiectasia in 8 SSc patients [72]. SSc telangiectasia are more resistant than sporadic telangiectasia to PDL and requires repeated treatment [81]. Skin atrophy is the end stage of skin fibrosis and the best treatment is to prevent or treat fibrosis. There are no studies evaluating drug efficacy in skin atrophy. In localized scleroderma, facial atrophy plastic surgery may be a therapeutic option [82].

Systemic lupus erythematosus working group

Systemic lupus erythematosus (SLE) is a multisystemic autoimmune disease affecting any organ in the body. Manifestations may range from mild symptoms to life threatening organ involvement. New insights into SLE pathogenesis have provided new tools for biologic targeted therapies, however the therapeutic strategy in SLE still requires a multidrug approach with wide immunosuppression. In fact, to date, most randomized controlled trials in SLE have failed and recommendations for disease management are mostly provided according to expert opinion be grounded on clinical evidence [83,84]. Currently, no biologic drug, but belimumab, is approved for SLE treatment, however growing evidence from real life support the use of rituximab even at repeated courses in refractory manifestations. Most data concern refractory Lupus nephritis (LN) and arthritis but hope exists for hematological, skin and neuropsychiatric manifestations as well. Targeted therapy is desirable in SLE due to side effects related to long-standing corticosteroid and immunosuppressive treatment and indeed several efforts in clinical research are aimed to this goal. On these bases, 6 statements were formulated and voted.

The use of biologic drugs in the treatment of specific SLE clinical features**Rituximab can be used in refractory lupus nephritis. LoE 2, GoR B**

LN is a predictor of poor prognosis, affecting nearly 50% of SLE patients over their disease course. Current therapies highlighted in European and American recommendations include mycophenolate mofetil and cyclophosphamide as a first line treatment in proliferative classes. Rituximab is endorsed as a second line treatment in refractory LN with the bulk of evidence coming from case series and notably from controlled or observational studies or registries [83-88]. In fact, prospective and retrospective studies, as well as case series and single case reports, showed 300 patients with refractory LN being treated with RTX at different dosing regimens and analysis revealed complete or partial response to RTX in approximately two thirds of patients [6], while RCTs have failed or were not convincing [89,90]. Interestingly, in the first controlled study heading rituximab versus cyclophosphamide, rituximab looked not inferior [91].

Rituximab and abatacept can be used in refractory arthritis. LoE 3, GoR C

Arthritis in SLE may range from mild inflammation of the joint to a deforming non-erosive arthritis (heralding Jaccoud's syndrome) or a rheumatoid-like arthritis with bone erosions. Treatment may diverge according to disease severity. Among biologics, rituximab and abatacept were the most likely candidates in light of their effectiveness in rheumatoid arthritis. Arthritis responded well to rituximab and abatacept in 2 randomized clinical trials [92,93] even though the evidence was not supported due to the randomized clinical trial failure. Most data on rituximab and abatacept on arthritis are provided by registries or case series.

TNFi can be used in refractory arthritis only for a short period of time. LoE 3, GoR C

Anti-TNF drugs are hardly advisable in SLE due to the risk of triggering autoimmunity, even though TNF is highly expressed in lupus target tissue due to local inflammation. TNF inhibitors were reported effective in small case series showing beneficial effects on arthritis, emphyagocytic syndrome or skin lesions [94].

Rituximab can be used in refractory hemolytic anemia, thrombocytopenia, mucocutaneous and neuropsychiatric lupus manifestations. LoE 3, GoR C

Few data are available on rituximab in refractory severe SLE manifestations. Some cases reported a successful experience in neuropsychiatric, hematological and severe mucocutaneous involvement [95]. Particularly, rituximab use was suggested in refractory thrombocytopenia [96] with most data coming from case reports or small case series; however, strong compelling evidence is still lacking.

To date there are no sufficient data to support the use of other biologics. LoE 5, GoR D

New biologics are in the pipeline for SLE that are being studied, which are not yet available.

Among them, promising results were provided for interferon (IFN) alpha inhibitors and particularly the anti-IFN receptor inhibitor anifrolumab [97]; other cytokine-targeted therapy include anti-IL-6 which is currently undervaluation [98].

Corticosteroid-sparing therapies in SLE, a possible role of biologic drugs

Biologics can be used as steroid sparing agents: belimumab and rituximab. Belimumab LoE 1b, GoR A; Rituximab: LoE 3, GoR C

Sparing steroids in among the emerging therapeutic targets and steroid tapering is supposed to be entailed in a stable remission [99]. Currently, the steroid sparing potential of most widespread biologics in SLE including rituximab and belimumab is increasing. In fact, belimumab was shown to decrease disease activity and flare rate, and accordingly the cumulative steroid dosage required to control disease activity [100].

By the off-label side, rituximab was shown to allow a lower daily prednisone dose in several open label studies and importantly, a longitudinal study on 50 LN patients showed how the joint use of rituximab and pulse steroids as initial therapy dramatically reduced the need for oral steroids in the follow-up [101].

Antiphospholipid syndrome working group

Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized by the coexistence of serological and clinical findings. The circulating antiphospholipid antibodies (aPL) are the serological hallmark. In the classification criteria, the presence of aPL is defined as: lupus anticoagulant (LA) and moderate to high titres of anticardiolipin (aCL) IgG and/or IgM antibodies and/or anti β 2glycoprotein I (a β 2GPI) IgG and/or IgM antibodies. The clinical criteria are defined as the presence of thrombotic events (arterial and/or venous and/or small vessels) and/or obstetric complications. In the classification criteria, pregnancy morbidity includes three or more recurrent early abortions, one or more foetal losses and one or more premature births due to (pre-)eclampsia or placental insufficiency [102]. Despite the recent improving in the understanding of pathogenic

mechanisms, the management of APS patients in some difficult cases could be considered an unmet need [103].

To date, the evidence-based recommendations of 2011 for thrombo-prophylaxis in patients with APS are based on data deriving from RCTs and observational studies [104]. The state of art of the treatment of patients with APS is based on long-term oral anticoagulation therapy for thrombotic manifestations and the combination of low dose aspirin (LDA) and low molecular weight heparin (LMWH) to prevent obstetric manifestations [105]. Conversely, the management of APS peculiar cases, considered areas of uncertainty, remains still unsolved. This is mainly due to the lack of appropriately designed multicentre studies.

Starting from these recommendations, the purpose of the present report was to better clarify the therapeutic choice in peculiar conditions that we can meet in daily practice. On these bases, 6 statements were formulated and voted. On these bases, 6 statements were formulated and voted.

Challenges in the management of APS patients, therapeutic choice in peculiar clinical conditions

Women who presented at least two miscarriages and persistent LA positivity alone should be considered for treatment. LoE 4, GoR D

Women who experienced two miscarriages and have Sydney laboratory criteria should be considered for treatment. LoE 1b GoR B

Women with low-titre anti-cardiolipin/anti-beta2GPI and clinical Sydney clinical criteria should be considered for treatment. LoE 2b, GoR B

The attention was focused on women who presented clinical and/or laboratory criteria that are not sufficient to classify them as affected by APS. In the last years, several obstetric manifestations, in addition to those included in the international consensus criteria, have been proposed as *obstetric morbidity associated with APS* (OMAPS). One of the main dilemmas is whether to treat these patients with non-criteria obstetrical manifestations (i.e. one or two early abortions) or with APS non-criteria laboratory diagnostic tests (low positive aCL or a β 2GPI). Prospective and retrospective cohort studies suggest that they may benefit from standard treatment for obstetric APS with LMWH plus LDA [106-109].

It could be useful to adopt an “add-on” strategy (hydroxychloroquine, corticosteroids, IVIG, apheresis) in refractory or high-risk (previous thrombosis, previous early severe pregnancy complications) cases of obstetric APS. LoE 2a, GoR C

Another crucial point is how to treat patients who develop a recurrence of thrombosis and/or pregnancy loss despite the treatment with standard therapy. In case of refractory OAPS or in high-risk OAPS patients (previous thrombosis, previous early severe pregnancy complications), data derive from systematic reviews [106-109]. In these cases, it could be useful to adopt an “add-on” strategy with other drugs such as hydroxychloroquine (HCQ), glucocorticoids, intravenous immunoglobulin (IVIG) or apheresis [110-116].

It could be useful to perform a stronger anticoagulation in APS patients who experienced arterial thrombosis recurrences. LoE 4, GoR D

Considering APS patients who experienced arterial thrombosis recurrences despite optimal anticoagulation, few data deriving from case report/case series suggest that it could be useful to perform a stronger anticoagulation, or an association of anticoagulant treatment plus LDA, or an “add-on” strategy with HCQ [104].

Medium-high titres and/or triple positive aPL carriers should be considered for treatment with LDA or also with HCQ in case of concomitant autoimmune diseases (such as SLE). LoE 3, GoR C

The aPL are a heterogeneous group of antibodies directed against toward phospholipid-binding plasma proteins or phospholipid-protein complexes [117]. It is possible to detect aPL also in asymptomatic subjects, the so-called *aPL carriers*. Concerning this group, several questions are still unsolved, such as the risk of developing thrombotic events and the need of a prophylactic treatment. Few data are available concerning the risk of thrombosis in aPL positive healthy subjects without a concomitant autoimmune disease [118]. Substantial evidence, reviewed in 2013 by Pengo et al. indicates that a ‘triple-positive’ aPL profile (presence of LA plus high titres of aCL and a β 2GPI) is strongly associated with thrombosis, in contrast to positivity for a single aPL [119]. Moreover, for aPL carriers risk stratification, a second level analysis could be performed in order to identify antibodies directed against the most pathogenic domain of β 2GPI, the domain I (DI). Indeed, the anti-DI β 2GPI, or a high DI/DIV-V ratio seem to be more predictive for thrombotic events [120]. Moving from these premises, medium-high titres aPL and/or triple positive aPL and/or more specific subsets of autoantibodies in aPL carriers should be considered for treatment with LDA or also with HCQ in case of concomitant autoimmune diseases such as SLE.

Sjogren’s syndrome working group

Sjögren's syndrome (SS) is autoimmune disease mainly affecting of the exocrine glands with associated inflammatory lymphocytic infiltrates of the affected glands. The main symptoms include the dryness of the mouth and eyes deriving from involvement of the salivary and lacrimal glands. Different therapeutic strategies have been proposed for SS; systemic therapy includes steroidal and non-steroidal anti-inflammatory agents, disease-modifying agents, and cytotoxic agents to address the extraglandular manifestations [121,122]. On these bases, 10 statements were formulated and voted.

Suitability of new diagnostic criteria in SS

ACR-EULAR new classification criteria have been developed and validated showing a very good performance in terms of sensitivity and specificity, and a high level of agreement with previously proposed criteria, mainly with American-European Consensus Criteria for Sjögren's Syndrome (AECG) criteria. LoE 1b, GoR A

The 2016 ACR-EULAR classification criteria [123] for primary (SS) are based on the weighted sum of five items: anti-SSA/Ro antibody positivity and focal lymphocytic sialadenitis with a focus score of ≥ 1 foci/4 mm², each scoring 3; an abnormal Ocular Staining Score of ≥ 5 (or van Bijsterveld score of ≥ 4), a Schirmer's test result of ≤ 5 mm/5 min and an unstimulated salivary flow rate of ≤ 0.1 mL/min, each scoring 1. A total score of ≥ 4 for the above items meet the criteria for SS. Sensitivity and specificity in the final validation cohort were 96% (95% CI 92% to 98%) and 95% (95% CI 92% to 97%), respectively. New criteria showed high level of agreement with previously proposed criteria, mainly with the AECG criteria [123].

The new criteria should represent the gold standard for classification of patients to be enrolled in future studies. Additional criteria of selection can be allowed to select particular subsets of patients for specific studies. LoE 5, GoR D

Besides the requirement of positive classification criteria, patients with SS may be stratified in subgroups, e.g., patients with positive anti-SSA/SSB antibodies or not, with more or less disease activity, dryness, fatigue. The issue of better stratification is being intensively investigated in cooperative international studies. Finally, since the specificity of classification criteria is not 100%, the clinical diagnosis of SS is in any case required in clinical practice.

SS disease activity: from prognosis to therapy

The use of EULAR SS Disease Activity Index (ESSDAI in real-life provides a reliable picture of systemic involvement in SS patients. Measurement of baseline systemic activity by ESSDAI is significantly associated with the prognosis. LoE 2b, GoR B

ESSDAI is a validated, reliable and sensitive to change tool to measure disease activity in SS patients in daily practice and clinical trials, providing a reliable picture of systemic manifestations in SS, as demonstrated in large cohorts of SS patients [124-127].

Baseline higher ESSDAI scores have been significantly associated with a poor prognosis. SS patients who present at diagnosis an ESSDAI score ≥ 14 and/or the presence of predictive immunological markers (lymphopenia, anti-La, monoclonal gammopathy, low complement and/or cryoglobulins), that are strongly associated with overall mortality, are at higher risk of death [128].

The ESSDAI, EULAR SS Patient Reported Index (ESSPRI), patient global assessment and the quality of life should be all evaluated, since they are complementary to assess the disease and since the correlation between them is low. LoE 2b, GoR B

Data from large cohort studies and therapeutic trials reported that the ESSPRI [129], more than ESSDAI, significantly correlated with health status [130-132] and health-related quality of life measures in SS patients [133-134].

Different studies demonstrated that systemic and patient scores are, however, poorly correlated, suggesting that these measures are complementary in the assessment of the disease and should be separately evaluated [135,136].

The histological assessment and the measurement of salivary flow should be included in SS trials. LoE 5, GoR D

Routine salivary biopsy has a crucial diagnostic and prognostic value in the assessment of SS patients [137,138]. By integrating histopathological data with clinical and molecular findings, different stages of lymphoproliferation with different risk of lymphoma evolution may be identified [139], providing also a potential useful instrument for patient stratification and for the design of SS trials.

The assessment of salivary gland secretory function, mainly through the measure of stimulated or unstimulated salivary flow rate, might be useful to stratify SS patients on the basis of their residual secretory potential in order to identify cases with residual salivary function, potential responders to

new treatments for what concerns dryness. Thus, the measurement of salivary flow should be included in all SS trials [140,141]. This functional study could be usefully accompanied by salivary gland ultrasonography investigation, to document glandular parenchymal damage and its possible deterioration over time in SS.

May clinical, hematological, and/or histological biomarkers improve SS management?

Clinical (persistent parotid swelling, purpura), hematological (low C4, cryoglobulinemia, leukopenia), and histological (germinal center-like structures) features are still insufficient as biomarkers of SS. Autoantibody formation and hypergammaglobulinemia are associated with extra-glandular manifestations. LoE 3b, GoR C

Traditional and new clinical and laboratory biomarkers are needed to improve the diagnosis of SS, to categorize subsets of patients, and to unmask pathogenic mechanisms which may represent novel therapeutic targets. LoE 5, GoR D

Research about biomarkers in SS has been mainly oriented, over the years, to the identification of predictors of evolution to malignant lymphoma, the main cause of SS poor survival and increased mortality [142-145]. Many biomarkers (such as cryoglobulinemia, often linked to cryoglobulinemic vasculitic features; persistent salivary glands swelling, usually parotid enlargement; hypocomplementemia; leukopenia; histologic detection of ectopic germinal center-like structures in salivary glands biopsy) are now available to help in daily practice the individuation of those SS patients at higher lymphoma risk, but they are not still exhaustive and require validation [145-155]. However, biomarkers could likely detect also SS patients more prone to worsen in different sicca or extraglandular manifestations, or more prone to respond to rather different treatments. Much research is currently dedicated to this issues.

Starting from a better comprehension of pathogenic mechanisms underlying SS, future efforts are needed to identify and validate new biomarkers, towards a stratification of well-defined patients subgroups for diagnostic, prognostic and therapeutic purposes.

Therapeutic strategies in SS, from conventional therapies to biologic drugs

Disease-modifying anti-rheumatic drugs (DMARDs) are given for systemic involvement; their administration is based on non-controlled studies and expert opinion. HCQ and MTX are

effective for arthritis, cyclophosphamide for severe vasculitis, small doses/short courses corticosteroids for constitutional symptoms, parotid gland enlargement and arthritis. LoE 5, GoR D

Evidence-based efficacy of conventional immunosuppressive therapy in SS treatment is limited, due to the lack of large controlled randomized studies or to the design of clinical trials [156-161]. However, expert opinion, non-controlled studies and daily clinical practice support their use [162-164].

Biologics may represent an effective treatment for SS in the future; B-cell depletion appears now recommended mainly for systemic manifestations and for persistent parotid swelling; residual glandular function is a prerequisite to enroll patients in trials to study sicca. LoE 4, GoR D

Larger multicentre, double blind studies, with the study of histology and biomarkers, are needed, applied in phenotypically homogeneous SS populations to be better stratified. LoE 5, GoR D

Three biologics, i.e., rituximab, belimumab and abatacept, proved their effectiveness in open studies for some extraglandular features of SS, but not for dryness, in general [165-170]. Parotid swelling, which represents a very important predictor of malignant lymphoma, may respond to these treatments, although any prevention of lymphoma evolution remains hypothetical. Cryoglobulinemic vasculitis benefits from rituximab [171,172]. Of note, upregulation of B-Cell Activating Factor (BAFF) may play an important role for ongoing B-cell lymphoproliferation [173]: it should be thoroughly investigated, and long-term treatment approaches should be also studied [174].

Patient inclusion criteria, disease duration, concomitant treatments, study endpoints, treatment duration and other parameters markedly differed in previous studies with biologics in SS. Many additional biologic drugs are also under investigation. A better stratification of SS represents a key preliminary step to improve future treatment studies.

Discussion

Autoimmune diseases are a complex set of diseases characterized by immune system activation and systemic involvement of the body. Although many progresses have been done in the last 15 years, and various practical guidelines for the management of these patients have been developed and

updated in order to improve the care of these patients so far, remission may be reached in less than 50% of patients and a personalized medicine, in this field, is still far away. Thus, the unmet need for autoimmune diseases care is one of the greatest public health problems in the developed countries. Furthermore, the gaps between guideline and real-world practice, and differences according to the region, culture, and medical environments may be the causes of different unmet needs for autoimmune disease care [175].

On these bases, a panel of international Experts were asked to identify, debate and formulate a list of key unmet needs within the field of rheumatology, serving as roadmap for research as well as support for clinicians. Experts were divided, according to their clinical and scientific expertise, in different disease-specific working groups, searching for the highest scientific answer for the identified unmet needs, within the most common autoimmune rheumatic diseases, by using SLR. To note, despite of the remarkable discoveries of the past 15 years [175-182], including the introduction of biologic treatments, targeting specific pathogenic molecules [182-187], the Experts identified several perceived unmet needs which still need a clear scientific definition and fulfilment such as the need to diagnose as early as possible autoimmune rheumatic diseases, to identify those patients developing complications as well as to elaborate therapeutic strategies using available drugs. It must be pointed out that treatment recommendations should usually be based on evidence. However, where evidence is missing, expert opinion has to be considered. Of course, the statements presented in this paper, sometimes may be not based on hard evidence, because strategic therapeutic trials, in which therapy was consistently adapted to reach a pre-specified treatment target and compared with a non-steered approach, are currently not available for many autoimmune diseases and available literature is still scarce. While the SRL provided any indirect evidence these statements may be only regarded as expert opinion and confirms the need for more research in the field.

At all the steps of this process, including the initial discussions by the steering committee, the identification of the unmet needs, the expansion of the working group and finally the development of statements for all the selected autoimmune rheumatic diseases, a large agreement was attained. Due to the differences among the disease and their heterogeneity a large number of statements was produced. Several of these statements may be considered as supportive or operational but covering the grey zone of the clinical practice in which no strong evidenced based recommendations exist, thus possibly helping physicians in the decision-making process.

The Expert panel discussed the using of different drugs in the treatment of rheumatic autoimmune diseases and the possible customized management plans that should be important in these

heterogeneous diseases. The majority of the drugs used in this context, mainly biologics, are expensive, and this aspect is always a concern, in those countries in which the health systems are progressively reducing the financial support, thus influencing how appropriately choosing, maintaining and discontinuing the therapy for these patients [182]. Furthermore, the management of comorbidities as well as of complications, is still a matter of debate lacking specific clinical trials [68,72,99,122,176,188], despite of it is well-known from epidemiological studies that patients with comorbid illnesses, independently from the primary disease, may be at higher risk of complications or death, less able to tolerate specific procedures, and less responsive to therapy, when compared to patients with the same primary disease who do not have these conditions [176,189-198].

Our statements are summarised in Table 1 and, like the majority of these types of statements or recommendations, further revision will be necessary in the next 3-4 years, or earlier, on the bases of new significant evidence that will accumulate in the next future. In conclusion, autoimmune rheumatic diseases have a substantial impact on patients in terms of function, impairment, activity limitation, participation and overall quality of life. The results derived from this international workshop confirmed that, despite of the enormous scientific production in these fields, several unmet needs in the management of autoimmune rheumatic diseases may be identified, confirming that the continued development of new therapeutic strategies and the better understanding and targeting of existing therapies is still an important field of research in order to address the existing needs for both patients and clinicians.

Competing interest

None

Acknowledgements

The Authors thank Mrs Federica Sensini for her technical assistance.

References

References:

[1] Wahren-Herlenius M, Dörner T. Immunopathogenic mechanisms of systemic autoimmune disease *Lancet*. 2013;382:819-31.

- [2] Pollard KM, Kono DH Requirements for innate immune pathways in environmentally induced autoimmunity. *BMC Med.* 2013;11:100.
- [3] Hernández- Rodríguez J, Ruíz-Ortiz E, Tomé A, Espinosa G, González-Roca E, Mensa-Vilaró A, Prieto-González S, Espígol-Frigolé G, Mensa J, Cardellach F, Grau JM, Cid MC, Yagüe J, Aróstegui JI, Cervera R. Clinical and genetic characterization of the autoinflammatory diseases diagnosed in an adult reference center. *Autoimmun Rev.* 2016;15:9-15
- [4] Murdaca G, Contatore M, Gulli R, Mandich P, Puppo F. Genetic factors and systemic sclerosis. *Autoimmun Rev.* 2016 May;15(5):427-32
- [5] Szentpétery Á, Horváth Á, Gulyás K, Pethö Z, Bhattoa HP, Szántó S, Szücs G, FitzGerald O, Schett G, Szekanecz Z. Effects of targeted therapies on the bone in arthritides. *Autoimmun Rev.* 2017 Mar;16(3):313-320.
- [6] Cipriani P, Ruscitti P, Carubbi F, Liakouli V, Giacomelli R. Methotrexate: an old new drug in autoimmune disease. *Expert Rev Clin Immunol.* 2014;10:1519-30.
- [7] Cipriani P, Ruscitti P, Carubbi F, Liakouli V, Giacomelli R. Methotrexate in rheumatoid arthritis: optimizing therapy among different formulations. Current and emerging paradigms. *Clin Ther.* 2014;36:427-35
- [8] Brouwers MC, Kho ME, Browman GP, Burgers JS, Cluzeau F, Feder G, Fervers B, Graham ID, Grimshaw J, Hanna SE, Littlejohns P, Makarski J, Zitzelsberger L; AGREE Next Steps Consortium CMAJ. AGREE II: advancing guideline development, reporting and evaluation in health care. 2010;182:E839-42.
- [9] Combe B, Landewe R, Daien CI, Hua C, Aletaha D, Álvaro-Gracia JM, Bakkers M, Brodin N, Burmester GR, Codreanu C, Conway R, Dougados M, Emery P, Ferraccioli G, Fonseca J, Raza K, Silva-Fernández L, Smolen JS, Skingle D, Szekanecz Z, Kvien TK, van der Helm-van Mil A, van Vollenhoven R. 2016 update of the EULAR recommendations for the management of early arthritis. *Ann Rheum Dis.* 2016 Dec 15. pii: annrheumdis-2016-210602. doi: 10.1136/annrheumdis-2016-210602. [Epub ahead of print]
- [10] Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, Nam J, Ramiro S, Voshaar M, van Vollenhoven R, Aletaha D, Aringer M, Boers M, Buckley CD, Buttgerit F, Bykerk V, Cardiel M, Combe B, Cutolo M, van Eijk-Hustings Y, Emery P, Finckh A, Gabay C, Gomez-Reino J, Gossec L, Gottenberg JE, Hazes JM, Huizinga T, Jani M, Karateev D,

Kouloumas M, Kvien T, Li Z, Mariette X, McInnes I, Mysler E, Nash P, Pavelka K, Poór G, Richez C, van Riel P, Rubbert-Roth A, Saag K, da Silva J, Stamm T, Takeuchi T, Westhovens R, de Wit M, van der Heijde D. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. *Ann Rheum Dis*. 2017 Mar 6. pii: annrheumdis-2016-210715. doi: 10.1136/annrheumdis-2016-210715. [Epub ahead of print].

[11] Schiff M, Weinblatt ME, Valente R, van der Heijde D, Citera G, Elegbe A, Maldonado M, Fleischmann R. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. *Ann Rheum Dis* 2014;73:86–94.

[12] Nam JL, Ramiro S, Gaujoux-Viala C, Takase K, Leon-Garcia M, Emery P, Gossec L, Landewe R, Smolen JS, Buch MH. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis. *Ann Rheum Dis* 2014;73:516–28.

[13] Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopez-Olivo MA, Tanjong Ghogomu E, Tugwell P. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. *Cochrane Database Syst Rev* 2009:CD007848.

[14] Salliot C, Finckh A, Katchamart W, Lu Y, Sun Y, Bombardier C, Keystone E. Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis. *Ann Rheum Dis* 2011;70:266–71.

[15] Barra L, Ha A, Sun L, Fonseca C, Pope J. Efficacy of biologic agents in improving the Health Assessment Questionnaire (HAQ) score in established and early rheumatoid arthritis: a meta-analysis with indirect comparisons. *Clin Exp Rheumatol* 2014;32:333–41.

[16] Callhoff J, Weiß A, Zink A, Listing J. Impact of biologic therapy on functional status in patients with rheumatoid arthritis--a meta-analysis. *Rheumatology (Oxford)* 2013;52:2127–35.

[17] Favalli EG, Pregnotato F, Biggioggero M, Meroni PL. The comparison of effects of biologic agents on rheumatoid arthritis damage progression is biased by period of enrollment: data from a systematic review and meta-analysis. *Seminars in Arthritis and Rheumatism* 2014;43:730–7.

- [18] Pierreisnard A, Issa N, Barnetche T, Richez C, Schaevebeke T. Meta-analysis of clinical and radiological efficacy of biologics in rheumatoid arthritis patients naive or inadequately responsive to methotrexate. *Joint Bone Spine* 2013;80:386–92.
- [19] Frazier-Mironer A, Dougados M, Mariette X, Cantagrel A, Deschamps V, Flipo R-M, Logeart I, Schaevebeke T, Sibilia J, Le Loët X, Combe B. Retention rates of adalimumab, etanercept and infliximab as first and second-line biotherapy in patients with rheumatoid arthritis in daily practice. *Joint Bone Spine* 2014;81:352–9.
- [20] Iannone F, Gremese E, Atzeni F, Biasi D, Botsios C, Cipriani P, Ferri C, Foschi V, Galeazzi M, Gerli R, Giardina A, Marchesoni A, Salaffi F, Ziglioli T, Lapadula G; Gruppo Italiano di Studio sulle Early Arthritides (GISEA). Longterm retention of tumor necrosis factor- α inhibitor therapy in a large italian cohort of patients with rheumatoid arthritis from the GISEA registry: an appraisal of predictors. *J Rheumatol* 2012;39:1179–84.
- [21] Marchesoni A, Zaccara E, Gorla R, Bazzani C, Sarzi-Puttini P, Atzeni F, Caporali R, Bobbio-Pallavicini F, Favalli EG. TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice. *Ann N Y Acad Sci* 2009;1173:837–46.
- [22] Flouri I, Markatseli TE, Voulgari PV, Boki KA, Papadopoulos I, Settas L, Zisopoulos D, Skopouli FN, Iliopoulos A, Bertias GK, Geborek P, Drosos AA, Boumpas DT, Sidiropoulos P. Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: Low rates of remission and 5-year drug survival. *Seminars in Arthritis and Rheumatism* 2013;43:447–57.
- [23] Souto A, Maneiro JR, Gomez-Reino JJ. Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care databases. *Rheumatology (Oxford)* 2015:kev374.
- [24] Favalli EG, Pregnolato F, Biggioggero M, Becciolini A, Penatti AE, Marchesoni A, Meroni PL. The 12-year retention rate of first-line tumor necrosis factor inhibitors in rheumatoid arthritis: Real-life data from a local registry. *Arthritis Care & Research* 2015: doi:10.1002/acr.22788.
- [25] Biggioggero M, Favalli EG. Ten-Year Drug Survival of Anti-TNF Agents in the Treatment of Inflammatory Arthritides. *Drug Dev Res* 2014;75 Suppl 1:S38–41.

- [26]. Gottenberg JE, Courvoisier DS, Hernández MV, Iannone F, Lie E, Canhao H, Canhã H, Pavelka K, Hetland ML, Turesson C, Mariette X, Finckh A. Rheumatoid factor and anti-citrullinated protein antibody positivity are associated with a better effectiveness of abatacept: Results from the Pan-European registry analysis. *Arthritis Rheumatol* 2016;68:1346-52.
- [26] Horák P, Skácelová M, Hejduk K, Smržová A, Pavelka K. Abatacept and its use in the treatment of rheumatoid arthritis (RA) in the Czech Republic-data from the ATTRA registry. *Clin Rheumatol* 2013;32:1451-8.
- [27] Gabay C, Riek M, Hetland ML, Hauge E-M, Pavelka K, Tomsic M, Canhao H, Chatzidionysiou K, Lukina G, Nordström DC, Lie E, Ancuta I, Hernández MV, van Riel PL, van Vollenhoven R, Kvien TK. Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a European collaborative study. *Ann Rheum Dis* 2015;75:1336-42.
- [28] Forsblad-d'Elia H, Bengtsson K, Kristensen LE, Jacobsson LTH. Drug adherence, response and predictors thereof for tocilizumab in patients with rheumatoid arthritis: results from the Swedish biologics register. *Rheumatology (Oxford)* 2015;54:1186-93.
- [29] Dougados M, Kissel K, Sheeran T, Tak PP, Conaghan PG, Mola EM, Schett G, Amital H, Navarro-Sarabia F, Hou A, Bernasconi C, Huizinga TW. Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). *Ann Rheum Dis*. 2013;72(1):43-50.
- [30] Gabay C, Emery P, van Vollenhoven R, Dikranian A, Alten R, Pavelka K, Klearman M, Musselman D, Agarwal S, Green J, Kavanaugh A; ADACTA Study Investigators. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. *Lancet*. 2013;381:1541-50.
- [31] Mori S. Management of Rheumatoid Arthritis Patients with Interstitial Lung Disease: Safety of Biological Antirheumatic Drugs and Assessment of Pulmonary Fibrosis. *Clin Med Insights Circ Respir Pulm Med*. 2015 Sep 8;9(Suppl 1):41-9.
- [32] Roubille C, Haraoui B. Interstitial lung diseases induced or exacerbated by DMARDs and biologic agents in rheumatoid arthritis: a systematic literature review. *Semin Arthritis Rheum*. 2014;43:613-26.

- [33] Furst DE, Kay J, Wasko MC, Keystone E, Kavanaugh A, Deodhar A, Murphy FT, Magnus JH, Hsia EC, Hsu B, Xu S, Rahman MU, Doyle MK. The effect of golimumab on haemoglobin levels in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. *Rheumatology (Oxford)*. 2013 Oct;52(10):1845-55.
- [34] Doyle MK, Rahman MU, Han C, Han J, Giles J, Bingham CO 3rd, Bathon J. Treatment with infliximab plus methotrexate improves anemia in patients with rheumatoid arthritis independent of improvement in other clinical outcome measures—a pooled analysis from three large, multicenter, double-blind, randomized clinical trials. *Semin Arthritis Rheum*. 2009;39:123-31.
- [35] Hashimoto M, Fujii T, Hamaguchi M, Furu M, Ito H, Terao C, Yamamoto K, Yamamoto W, Matsuo T, Mori M, Ohmura K, Kawabata H, Mimori T. Increase of hemoglobin levels by anti-IL-6 receptor antibody (tocilizumab) in rheumatoid arthritis. *PLoS One*. 2014 May 30;9:e98202.
- [36] Isaacs JD, Harari O, Kobold U, Lee JS, Bernasconi C. Effect of tocilizumab on haematological markers implicates interleukin-6 signalling in the anaemia of rheumatoid arthritis. *Arthritis Res Ther*. 2013;15:R204.
- [37] Song SN, Iwahashi M, Tomosugi N, Uno K, Yamana J, Yamana S, Isobe T, Ito H, Kawabata H, Yoshizaki K. Comparative evaluation of the effects of treatment with tocilizumab and TNF- α inhibitors on serum hepcidin, anemia response and disease activity in rheumatoid arthritis patients. *Arthritis Res Ther*. 2013 Oct 2;15:R141.
- [38] Puéchal X, Gottenberg JE, Berthelot JM, Gossec L, Meyer O, Morel J, Wendling D, de Bandt M, Houvenagel E, Jamard B, Lequerré T, Morel G, Richette P, Sellam J, Guillevin L, Mariette X; Investigators of the AutoImmunity Rituximab Registry. Rituximab therapy for systemic vasculitis associated with rheumatoid arthritis: Results from the AutoImmunity and Rituximab Registry. *Arthritis Care Res (Hoboken)*. 2012;64:331-9.
- [39] van Herwaarden N, den Broeder AA, Jacobs W, van der Maas A, Bijlsma JW, van Vollenhoven RF, van den Bemt BJ. Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity. *Cochrane Database Syst Rev*. 2014 Sep 29:CD010455.
- [40] Ferriols-Lisart R, Ferriols-Lisart F. Dose modifications of anti-TNF drugs in rheumatoid arthritis patients under real-world settings: a systematic review. *Rheumatol Int*. 2015;35:1193-210.

- [41] Scherer HU, Dörner T, Burmester GR. Patient-tailored therapy in rheumatoid arthritis: an editorial review. *Curr Opin Rheumatol*. 2010;22:237-45.
- [42] Emery P, Dörner T. Optimising treatment in rheumatoid arthritis: a review of potential biological markers of response. *Ann Rheum Dis*. 2011;70:2063-70
- [43] Cuppen BV, Welsing PM, Sprengers JJ, Bijlsma JW, Marijnissen AC, van Laar JM, Lafeber FP, Nair SC. Personalized biological treatment for rheumatoid arthritis: a systematic review with a focus on clinical applicability. *Rheumatology (Oxford)*. 2016;55:826-39.
- [44] Maneiro RJ, Salgado E, Carmona L, Gomez-Reino JJ. Rheumatoid factor as predictor of response to abatacept, rituximab and tocilizumab in rheumatoid arthritis: Systematic review and meta-analysis. *Semin Arthritis Rheum*. 2013;43:9-17.
- [45] Benucci M, Manfredi M, Puttini PS, Atzeni F. Predictive factors of response to rituximab therapy in rheumatoid arthritis: What do we know today? *Autoimmun Rev*. 2010;9:801-3.
- [46] Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland ML, Tarp U, Gabay C, van Riel PL, Nordström DC, Gomez-Reino J, Pavelka K, Tomsic M, Kvien TK, van Vollenhoven. RF. Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries. *Ann Rheum Dis*. 2011;70:1575-80.
- [47] Couderc M, Mathieu S, Pereira B, Glace B, Soubrier M. Predictive factors of rituximab response in rheumatoid arthritis: results from a French university hospital. *Arthritis Care Res (Hoboken)*. 2013;65:648-52
- [48] Rudwaleit M, van der Heijde D, Landewé R, Listing J, Akkoc N, Brandt J, Braun J, Chou CT, Collantes-Estevez E, Dougados M, Huang F, Gu J, Khan MA, Kirazli Y, Maksymowych WP, Mielants H, Sørensen IJ, Ozgocmen S, Roussou E, Valle-Oñate R, Weber U, Wei J, Sieper J. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. *Ann Rheum Dis*. 2009;68:777-83.
- [49] Rudwaleit M, Landewé R, van der Heijde D, Listing J, Brandt J, Braun J, Burgos-Vargas R, Collantes-Estevez E, Davis J, Dijkmans B, Dougados M, Emery P, van der Horst-Bruinsma IE, Inman R, Khan MA, Leirisalo-Repo M, van der Linden S, Maksymowych WP, Mielants H, Olivieri I, Sturrock R, de Vlam K, Sieper J. The development of Assessment of SpondyloArthritis

international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. *Ann Rheum Dis.* 2009;68:770-6.

[50] Sieper J, Listing J, Poddubnyy D, Song IH, Hermann KG, Callhoff J, Syrbe U, Braun J, Rudwaleit M. Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2 years on radiographic progression of the spine: results from a randomised multicentre trial (ENRADAS). *Ann Rheum Dis.* 2016;75:1438-43.

[51] Kroon F, Landewé R, Dougados M, van der Heijde D. Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis. *Ann Rheum Dis.* 2012;71:1623-9.

[52] Wanders A, Heijde Dv, Landewé R, Béhier JM, Calin A, Olivieri I, Zeidler H, Dougados M. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. *Arthritis Rheum.* 2005;52:1756-65

[53] Kroon FP, van der Burg LR, Ramiro S, Landewé RB, Buchbinder R, Falzon L, van der Heijde D. Non-steroidal anti-inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis). *Cochrane Database Syst Rev.* 2015:CD010952.

[54] Poddubnyy D, Rudwaleit M, Haibel H, Listing J, Märker-Hermann E, Zeidler H, Braun J, Sieper J. Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. *Ann Rheum Dis.* 2012;71:1616-22.

[55] Song IH, Hermann K, Haibel H, Althoff CE, Listing J, Burmester G, Krause A, Bohl-Bühler M, Freundlich B, Rudwaleit M, Sieper J. Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial. *Ann Rheum Dis.* 2011;70:590-6.

[56] Braun J, Zochling J, Baraliakos X, Alten R, Burmester G, Grasedyck K, Brandt J, Haibel H, Hammer M, Krause A, Mielke F, Tony HP, Ebner W, Gömör B, Hermann J, Zeidler H, Beck E, Baumgaertner M, Sieper J. Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: a multicentre randomised controlled trial. *Ann Rheum Dis.* 2006;65:1147-53.

- [57] Baraliakos X, Listing J, Rudwaleit M, Brandt J, Sieper J, Braun J. Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor alpha antibody infliximab. *Ann Rheum Dis*. 2005;64:1462-6.
- [58] van der Heijde D, Landewé R, Baraliakos X, Houben H, van Tubergen A, Williamson P, Xu W, Baker D, Goldstein N, Braun J; Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group. Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. *Arthritis Rheum*. 2008;58:3063-70.
- [59] Baraliakos X, Haibel H, Listing J, Sieper J, Braun J. Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis. *Ann Rheum Dis*. 2014;73:710-5.
- [60] van der Heijde D, Salonen D, Weissman BN, Landewé R, Maksymowych WP, Kupper H, Ballal S, Gibson E, Wong R; Canadian (M03-606) study group.; ATLAS study group. Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. *Arthritis Res Ther*. 2009;11:R127.
- [61] Braun J, Baraliakos X, Hermann KG, Deodhar A, van der Heijde D, Inman R, Beutler A, Zhou Y, Xu S, Hsu B. The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial. *Ann Rheum Dis*. 2014;73:1107-13.
- [62] Cantarini L, Fabbroni M, Talarico R, Costa L, Caso F, Cuneo GL, Frediani B, Faralli G, Vitale A, Brizi MG, Sabadini L, Galeazzi M. Effectiveness of Adalimumab in Non-radiographic Axial Spondyloarthritis: Evaluation of Clinical and Magnetic Resonance Imaging Outcomes in a Monocentric Cohort. *Medicine (Baltimore)*. 2015;94:e1170
- [63] Callhoff J, Sieper J, Weiß A, Zink A, Listing J. Efficacy of TNF α blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis. *Ann Rheum Dis*. 2015;74:1241-8
- [64] Ren L, Li J, Luo R, Tang R, Zhu S, Wan L. Efficacy of antitumor necrosis factor(α) agents on patients with ankylosing spondylitis. *Am J Med Sci*. 2013;346:455-61.
- [65] Escalas C, Trijau S, Dougados M. Evaluation of the treatment effect of NSAIDs/TNF blockers according to different domains in ankylosing spondylitis: results of a meta-analysis. *Rheumatology (Oxford)*. 2010;49:1317-25.

- [66] Park W, Hrycaj P, Jeka S, Kovalenko V, Lysenko G, Miranda P, Mikazane H, Gutierrez-Ureña S, Lim M, Lee YA, Lee SJ, Kim H, Yoo DH, Braun J. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. *Ann Rheum Dis.* 2013;72:1605-12.
- [67] Baji P, Péntek M, Szántó S, Géher P, Gulácsi L, Balogh O, Brodszky V. Comparative efficacy and safety of biosimilar infliximab and other biological treatments in ankylosing spondylitis: systematic literature review and meta-analysis. *Eur J Health Econ.* 2014;15 Suppl 1:S45-52.
- [68] Arends S, Brouwer E, van der Veer E, Groen H, Leijnsma MK, Houtman PM, Th A Jansen TL, Kallenberg CG, Spoorenberg A. Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study. *Arthritis Res Ther.* 2011;13:R94.
- [69] Baraliakos X, Listing J, Brandt J, Zink A, Alten R, Burmester G, Gromnica-Ihle E, Kellner H, Schneider M, Sörensen H, Zeidler H, Rudwaleit M, Sieper J, Braun J. Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. *Arthritis Res Ther.* 2005;7:R439-44.
- [70] Závada J, Uher M, Sisol K, Forejtová Š, Jarošová K, Mann H, Vencovský J, Pavelka K. A tailored approach to reduce dose of anti-TNF drugs may be equally effective, but substantially less costly than standard dosing in patients with ankylosing spondylitis over 1 year: a propensity score-matched cohort study. *Ann Rheum Dis.* 2016;75:96-102.
- [71] Arends S, van der Veer E, Kamps FB, Houtman PM, Bos R, Bootsma H, Brouwer E, Spoorenberg A. Patient-tailored dose reduction of TNF- α blocking agents in ankylosing spondylitis patients with stable low disease activity in daily clinical practice. *Clin Exp Rheumatol.* 2015;33:174-8
- [72] Ferri C, Sebastiani M, Lo Monaco A, Iudici M, Giuggioli D, Furini F, Manfredi A, Cuomo G, Spinella A, Colaci M, Govoni M, Valentini G. Systemic sclerosis evolution of disease pathomorphosis and survival. *Autoimmun Rev* 2014;13:1026-34
- [73] van Laar JM, Farge D, Sont JK, Naraghi K, Marjanovic Z, Larghero J, Schuerwegh AJ, Marijt EW, Vonk MC, Schattenberg AV, Matucci-Cerinic M, Voskuyl AE, van de Loosdrecht AA, Daikeler T, Kötter I, Schmalzing M, Martin T, Lioure B, Weiner SM, Kreuter A, Deligny C,

Durand JM, Emery P, Machold KP, Sarrot-Reynauld F, Warnatz K, Adoue DF, Constans J, Tony HP, Del Papa N, Fassas A, Himsel A, Launay D, Lo Monaco A, Philippe P, Quéré I, Rich É, Westhovens R, Griffiths B, Saccardi R, van den Hoogen FH, Fibbe WE, Socié G, Gratwohl A, Tyndall A; EBMT/EULAR Scleroderma Study Group. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. *JAMA* 2014;311:2490-8.

[74] Nihtyanova S, Brough GM, Black CM, Denton CP. Mycophenolate mofetil in diffuse cutaneous systemic sclerosis--a retrospective analysis. *Rheumatology (Oxford)* 2007;46:442-5

[75] Allanore Y, Meune C, Vonk MC, Airo P, Hachulla E, Caramaschi P, Riemekasten G, Cozzi F, Beretta L, Derk CT, Komócsi A, Farge D, Balbir A, Ricciari V, Distler O, Chialà A, Del Papa N, Simic KP, Ghio M, Stamenkovic B, Rednic S, Host N, Pellerito R, Zegers E, Kahan A, Walker UA, Matucci-Cerinic M; EUSTAR co-authors.. Prevalence and factors associated with left ventricular dysfunction in the EULAR Scleroderma Trial and Research group (EUSTAR) database of patients with systemic sclerosis. *Ann Rheum Dis* 2010;69:218-21

[76] Lee SW, Choi EY, Jung SY, Choi ST, Lee SK, Park YB. E/E' ratio is more sensitive than E/A ratio for detection of left ventricular diastolic dysfunction in patients with systemic sclerosis. *Clin Exp Rheumatol* 2010;28(suppl58):S12-17.

[77] Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, Arriola E, Silver R, Strange C, Bolster M, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel DE, Theodore A, Simms R, Wise R, Wigley F, White B, Steen V, Read C, Mayes M, Parsley E, Mubarak K, Connolly MK, Golden J, Olman M, Fessler B, Rothfield N, Metersky M; Scleroderma Lung Study Research Group. Scleroderma Lung Study Research Group. Cyclophosphamide versus placebo in scleroderma lung disease. *N Engl J Med* 2006;354:2655-66.

[78] Iudici M, Moroncini G, Cipriani P, Giacomelli R, Gabrielli A, Valentini G. Where are we going in the management of interstitial lung disease in patients with systemic sclerosis? *Autoimmun Rev.* 2015;14:575-8

[79] Gyger G, Baron M. Systemic Sclerosis: Gastrointestinal Disease and Its Management. *Rheum Dis Clin N Am* 2015;41:459-73.

- [80] Walker KM, Pope J et al. Treatment of systemic sclerosis complications: what to use when first-line treatment fails--a consensus of systemic sclerosis experts. *Sem Arthritis Rheum* 2012;42:42-55.
- [81] Halachmi S, Gabari O, Cohen S et al. Telangiectasis in CREST syndrome and systemic sclerosis: correlation of clinical and pathological features with response to pulsed dye laser treatment. *Lasers Med Sci* 2014;29:137-40
- [82] Careta MF, Romiti R. Localized scleroderma: clinical spectrum and therapeutic update. *An Bras Dermatol* 2015;90:62-73
- [83] Gatto M, Saccon F, Zen M, Bettio S, Iaccarino L, Punzi L, Doria A. Success and failure of biological treatment in systemic lupus erythematosus: A critical analysis. *J Autoimmun.* 2016;74:94-105.
- [84] Gatto M, Kiss E, Naparstek Y, Doria A. In-/off-label use of biologic therapy in systemic lupus erythematosus. *BMC Med* 2014;17:12:30.
- [85] Davies RJ, Sangle SR, Jordan NP, Aslam L, Lewis MJ, Wedgwood R, D'Cruz DP.. Rituximab in the treatment of resistant lupus nephritis: therapy failure in rapidly progressive crescentic lupus nephritis. *Lupus* 2013;22:574-82
- [86] Iaccarino L, Bartoloni E, Carli L, Ceccarelli F, Conti F, De Vita S, Ferraccioli G, Galeazzi M, Gatto M, Gerli R, Govoni M, Gremese E, Iuliano A, Mansutti E, Moroni G, Mosca M, Nalli C, Naretto C, Padovan M, Palma L, Raffiotta F, Roccatello D, Tincani A, Valesini G, Zen M, Doria A. Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian Multicentre Registry. *Clin Exp Rheumatol* 2015;33:449-56.
- [87] Terrier B, Amoura Z, Ravaud P, Hachulla E, Jouenne R, Combe B, Bonnet C, Cacoub P, Cantagrel A, de Bandt M, Fain O, Fautrel B, Gaudin P, Godeau B, Harlé JR, Hot A, Kahn JE, Lambotte O, Larroche C, Léone J, Meyer O, Pallot-Prades B, Pertuiset E, Quartier P, Schaerverbeke T, Sibilia J, Somogyi A, Soubrier M, Vignon E, Bader-Meunier B, Mariette X, Gottenberg JE; Club Rhumatismes et Inflammation. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry. *Arthritis Rheum* 2010;62:2458-66.
- [88] Weidenbusch M, Römmele C, Schröttle A, Anders HJ. Beyond the LUNAR trial. Efficacy of rituximab in refractory lupus nephritis. *Nephrol Dial Transplant* 2013;28:106–111.

- [89] Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J, Maciuca R, Zhang D, Garg JP, Brunetta P, Appel G; LUNAR Investigator Group.. Efficacy and Safety of Rituximab in Patients With Active Proliferative Lupus Nephritis. The Lupus Nephritis Assessment With Rituximab Study. *Arthritis Rheum* 2012;64:1215-1226.
- [90] Zhang J, Zhao Z, Hu X. Effect of Rituximab on Serum Levels of Anti-C1q and Antineutrophil Cytoplasmic Autoantibodies in Refractory Severe Lupus Nephritis. *Cell Biochem Biophys* 2015;72:197-201.
- [91] Moroni G, Gallelli B, Sinico R, Romano G, Sinigaglia L, Messa P. Rituximab versus oral cyclophosphamide for treatment of relapses of proliferative lupus nephritis: a clinical observational study. *Ann Rheum Dis* 2012;71:1751-2.
- [92] Merrill JT, Neuwelt C, Wallace D, Shanahan J, Latinis K, Oates J. Efficacy and Safety of Rituximab in Moderately-to-Severely Active Systemic Lupus Erythematosus The Randomized, Double-Blind, Phase II/III Systemic Lupus Erythematosus Evaluation of Rituximab Trial. *Arthritis Rheum* 2010;62:222-233.
- [93] Merrill JT, Burgos-Vargas R, Westhovens R, Chalmers A, D'Cruz D, Wallace DJ, Bae SC, Sigal L, Becker JC, Kelly S, Raghupathi K, Li T, Peng Y, Kinaszchuk M, Nash P.. The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. *Arthritis Rheum* 2010;62:3077-87.
- [94] Uppal SS, Hayat SJ, Raghupathy R: Efficacy and safety of infliximab in active SLE: a pilot study. *Lupus* 2009;18:690–697.
- [95] Hofmann SC, Leandro MJ, Morris SD, Isenberg DA. Effects of rituximab-based B-cell depletion therapy on skin manifestations of lupus erythematosus--report of 17 cases and review of the literature. *Lupus* 2013;22:932-9
- [96] Jiang B, Li T, Guo L, Shen H, Ye S, Chen S. Efficacy and Safety of Rituximab in Systemic Lupus Erythematosus and Sjögren Syndrome Patients With Refractory Thrombocytopenia: A Retrospective Study of 21 Cases. *J Clin Rheumatol* 2015;21:244-50.
- [97] Furie R, Merrill JT, Werth V, Kamashta M, Kalunian K, Brohawn P, et al. Anifrolumab, an anti-interferon alpha receptor monoclonal antibody, in moderate to severe SLE. Abstract no. 3223 presented at the ACR/ARHP annual meeting, San Francisco, CA, November 6-11, 2015.

- [98] Rovin R, van Vollenhoven R, Aranow C, Wagner C, Gordon R, Zhuang Y, et al. A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of treatment with sirukumab (CNTO 136) in patients with active lupus nephritis. *Arthritis Rheumatol* 2016 [Epub ahead of print].
- [99] Doria A, Gatto M, Zen M, Iaccarino L, Punzi L. Optimizing outcome in SLE: treating-to-target and definition of treatment goals. *Autoimmun Rev* 2014;13:770-7.
- [100] van Vollenhoven RF, Petri M, Wallace DJ, Roth DA, Molta CT, Hammer AE, Tang Y, Thompson A. Cumulative corticosteroids over 52 weeks in patients with systemic lupus erythematosus: Pooled analyses from the phase III belimumab trials. *Arthritis Rheumatol*. 2016;68:2184-92.
- [101] Condon MB, Ashby D, Pepper RJ, Cook HT, Levy JB, Griffith M, Cairns TD, Lightstone L. Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. *Ann Rheum Dis* 2013;72:1280-6.
- [102] Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, DE Groot PG, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). *J Thromb Haemost* 2006; 4:295–306.
- [103] Espinosa G, Cervera R. Current treatment of antiphospholipid syndrome: lights and shadows. *Nat Rev Rheumatol* 2015; 11:586-96.
- [104] Ruiz-Irastorza G, Cuadrado MJ, Ruiz-Arruza I, Brey R, Crowther M, Derksen R, Erkan D, Krilis S, Machin S, Pengo V, Pierangeli S, Tektonidou M, Khamashta M. Evidence-based recommendations for the prevention and longterm management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on Antiphospholipid Antibodies. *Lupus* 2011; 20:206–218.
- [105] Chighizola CB, Raschi E, Borghi MO, Meroni PL. Update on the pathogenesis and treatment of the antiphospholipid syndrome. *Curr Opin Rheumatol* 2015; 27:476-82.
- [106] Arachchillage DRJ, Machin SJ, Mackie IJ, Cohen H. Diagnosis and management of non-criteria obstetric antiphospholipid syndrome. *Thromb Haemost* 2014; 113:13–19.

- [107] Del Ross T, Ruffatti A, Visentin MS, Tonello M, Calligaro A, Favaro M, Hoxha A, Punzi L. Treatment of 139 pregnancies in antiphospholipid-positive women not fulfilling criteria for antiphospholipid syndrome: a retrospective study. *J Rheumatol* 2013; 40:425–429.
- [108] Clark CA, Spitzer KA, Laskin CA. Obstetric antiphospholipid syndrome: has the black swan swallowed a red herring? *J Rheumatol* 2015; 42:155-7.
- [109] Meroni PL, Chighizola CB, Gerosa M, Trespidi L, Acaia B. Obstetric antiphospholipid syndrome: lobsters only? Or should we also look for selected red herrings? *J Rheumatol* 2015;42:158-60.
- [110] Alijotas-Reig J. Treatment of refractory obstetric antiphospholipid syndrome: the state of the art and new trends in the therapeutic management. *Lupus* 2013;22:6–17.
- [111] Mekinian A, Costedoat-Chalumeau N, Masseau A, Tincani A, De Caroli S, Alijotas-Reig J, Ruffatti A, Ambrozic A, Botta A, Le Guern V, Fritsch-Stork R, Nicaise-Roland P, Carbonne B, Carbillon L, Fain O. Obstetrical APS: is there a place for hydroxychloroquine to improve the pregnancy outcome? *Autoimmun Rev* 2015;14:23–29.
- [112] Bramham K, Thomas M, Nelson-Piercy C, Khamashta M, Hunt BJ. First-trimester low-dose prednisolone in refractory antiphospholipidantibody-related pregnancy loss. *Blood* 2011; 117:6948–6951.
- [113] Triolo G, Ferrante A, Ciccia F, Accardo-Palumbo A, Perino A, Castelli A, Giarratano A, Licata G. Randomized study of subcutaneous low molecular weight heparin plus aspirin versus intravenous immunoglobulins in the treatment of recurrent fetal loss associated with antiphospholipid antibodies. *Arthritis Rheum* 2003;48:728–731.
- [114] Branch D, Peaceman AM, Druzin M, Silver RK, El-Sayed Y, Silver RM, Esplin MS, Spinnato J, Harger J. A multicenter placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy. The Pregnancy Loss Study Group. *Am J Obstet Gynecol* 2000;182:122–127.
- [115] Dendrinou S, Sakkas E, Makrakis E. Low-molecular-weight heparin versus intravenous immunoglobulin for recurrent abortion associated with antiphospholipid antibody syndrome. *Int J Gynaecol Obstet* 2009;104:223–225.

- [116] Vaquero E, Lazzarin N, Valensise H, Menghini S, Di Pierro G, Cesa F, Romanini C. Pregnancy outcome in recurrent spontaneous abortion associated with antiphospholipid antibodies: a comparative study of intravenous immunoglobulin versus prednisolone plus low-dose aspirin. *Am J Reprod Immunol* 2001;45:174–179.
- [117] Alessandri C, Conti F, Pendolino M, Mancini R, Valesini G. New autoantigens in the antiphospholipid syndrome. *Autoimmun Rev* 2011;10:609-16.
- [118] Finazzi G, Brancaccio V, Moia M, Ciaverella N, Mazzucconi MG, Schinco PC, Ruggeri M, Pogliani EM, Gamba G, Rossi E, Baudo F, Manotti C, D'Angelo A, Palareti G, De Stefano V, Berrettini M, Barbui T. Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry. *Am J Med* 1996; 100:530-6.
- [119] Pengo V, Banzato A, Denas G, Jose SP, Bison E, Hoxha A, Ruffatti A. Correct laboratory approach to APS diagnosis and monitoring. *Autoimmun Rev* 2013; 12:832-4.
- [120] Pericleous C, Ferreira I, Borghi O et al. Measuring IgA anti- β 2-Glycoprotein I and IgG/IgA anti-domain I antibodies adds value to current serological assays for the antiphospholipid syndrome. *PLoS One* 2016;11:e0156407.
- [121] Fox RI. Sjögren's syndrome *Lancet*. 2005;366:321-31.
- [122] Voulgarelis M, Tzioufas AG. Pathogenetic mechanisms in the initiation and perpetuation of Sjögren's syndrome. *Nat Rev Rheumatol*. 2010;6:529-37.
- [123] Shiboski CH, Shiboski SC, Seror R, Criswell LA, Labetoulle M, Lietman TM, Rasmussen A, Scofield H, Vitali C, Bowman SJ, Mariette X. International Sjögren's Syndrome Criteria Working Group. 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren's syndrome: A consensus and data-driven methodology involving three international patient cohorts. *Ann Rheum Dis*. 2017;76:9-16.
- [124] Seror R, Ravaud P, Bowman SJ, Baron G, Tzioufas A, Theander E, Gottenberg JE, Bootsma H, Mariette X, Vitali C; EULAR Sjögren's Task Force. EULAR Sjögren's Task Force.. EULAR Sjögren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjögren's syndrome. *Ann Rheum Dis*. 2010;69:1103-9.
- [125] Seror R, Theander E, Brun JG, Ramos-Casals M, Valim V, Dörner T, Bootsma H, Tzioufas A, Solans-Laqué R, Mandl T, Gottenberg JE, Hachulla E, Sivils KL, Ng WF, Fauchais AL,

Bombardieri S, Valesini G, Bartoloni E, Saraux A, Tomsic M, Sumida T, Nishiyama S, Caporali R, Kruize AA, Vollenweider C, Ravaud P, Vitali C, Mariette X, Bowman SJ; EULAR Sjögren's Task Force. Validation of EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient indexes (ESSPRI). *Ann Rheum Dis*. 2015;74:859-66.

[126] Ramos-Casals M, Brito-Zerón P, Solans R, Camps MT, Casanovas A, Sopeña B, Díaz-López B, Rascón FJ, Qanneta R, Fraile G, Pérez-Alvarez R, Callejas JL, Ripoll M, Pinilla B, Akasbi M, Fonseca E, Canora J, Nadal ME, de la Red G, Fernández-Regal I, Jiménez-Heredia I, Bosch JA, Ayala MD, Morera-Morales L, Maure B, Mera A, Ramentol M, Retamozo S, Kostov B; SS Study Group.; Autoimmune Diseases Study Group (GEAS) of the Spanish Society of Internal Medicine (SEMI). Systemic involvement in primary Sjogren's syndrome evaluated by the EULAR-SS disease activity index: analysis of 921 Spanish patients (GEAS-SS Registry). *Rheumatology (Oxford)*. 2014;53:321-31.

[127] Seror R, Mariette X, Bowman S, Baron G, Gottenberg JE, Bootsma H, Theander E, Tzioufas A, Vitali C, Ravaud P; European League Against Rheumatism Sjögren's Task Force. Accurate detection of changes in disease activity in primary Sjögren's syndrome by the European League Against Rheumatism Sjögren's Syndrome Disease Activity Index. *Arthritis Care Res (Hoboken)*. 2010;62:551-8.

[128] Brito-Zerón P, Kostov B, Solans R, Fraile G, Suárez-Cuervo C, Casanovas A, Rascón FJ, Qanneta R, Pérez-Alvarez R, Ripoll M, Akasbi M, Pinilla B, Bosch JA, Nava-Mateos J, Díaz-López B, Morera-Morales ML, Gheitasi H, Retamozo S, Ramos-Casals M; SS Study Group, Autoimmune Diseases Study Group (GEAS), Spanish Society of Internal Medicine (SEMI).. Systemic activity and mortality in primary Sjögren syndrome: predicting survival using the EULAR-SS Disease Activity Index (ESSDAI) in 1045 patients. *Ann Rheum Dis*. 2016 Feb;75:348-5.

[129] Seror R, Ravaud P, Mariette X, Bootsma H, Theander E, Hansen A, Ramos-Casals M, Dörner T, Bombardieri S, Hachulla E, Brun JG, Kruize AA, Praprotnik S, Tomsic M, Gottenberg JE, Devauchelle V, Devita S, Vollenweider C, Mandl T, Tzioufas A, Carsons S, Saraux A, Sutcliffe N, Vitali C, Bowman SJ; EULAR Sjögren's Task Force. EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjogren's syndrome. *Ann Rheum Dis*. 2011;70:968-72.

[130] Lendrem D, Mitchell S, McMeekin P, Gompels L, Hackett K, Bowman S, Price E, Pease CT, Emery P, Andrews J, Lanyon P, Hunter J, Gupta M, Bombardieri M, Sutcliffe N, Pitzalis C,

McLaren J, Cooper A, Regan M, Giles I, Isenberg D, Saravanan V, Coady D, Dasgupta B, McHugh N, Young-Min S, Moots R, Gendi N, Akil M, Griffiths B, Ng WF; UK primary Sjögren's Syndrome Registry.. Do the EULAR Sjögren's syndrome outcome measures correlate with health status in primary Sjögren's syndrome? *Rheumatology (Oxford)*. 2015;54:655-9.

[131] Ng W-F, Mitchell S, Lendrem D, Bowman SJ, Price E, Pease C, et al. How good are the EULAR sjögren's syndrome disease activity index (ESSDAI), and eular sjögren's syndrome patients reported index (ESSPRI) in predicting health status in primary sjögren's syndrome? *Ann Rheum Dis*. 2012;71:553.

[132] Ng W-F, Bowman S, Griffiths B, Mitchell S, Price E, Pease C, et al. Relationship between disease activity of primary Sjogren's syndrome and Patient reported outcome – data from an interim analysis of the UK primary Sjögren's syndrome registry *Ann Rheum Dis*. 2011;70:510.

[133] Cornec D, Devauchelle-Pensec V, Mariette X, Jousse-Joulin S, Berthelot JM, Perdriger A, Puéchal X, Le Guern V, Sibilia J, Gottenberg JE, Chiche L, Hachulla E, Hatron PY, Goeb V, Hayem G, Morel J, Zarnitsky C, Dubost JJ, Saliou P, Pers Dds JO, Seror R, Saraux A. Severe Health-Related Quality-of-life Impairment in Active Primary Sjögren's Syndrome Is Driven by Patient-Reported Outcomes: Data from a Large Therapeutic Trial. *Arthritis Care Res (Hoboken)*. 2016 Jul 7. Epub ahead of print doi: 10.1002/acr.22974.

[134] Cho HJ, Yoo JJ, Yun CY, Kang EH, Lee HJ, Hyon JY, Song YW, Lee YJ. The EULAR Sjogren's syndrome patient reported index as an independent determinant of health-related quality of life in primary Sjogren's syndrome patients: in comparison with non-Sjogren's sicca patients. *Rheumatology (Oxford)*. 2013;52:2208-17.

[135] Seror R, Gottenberg J-E, Devauchelle-Pensec V, Dubost JJ, Le Guern V, Dieudé P et al Assessment of systemic disease activity is complementary to assessment of patient's symptoms in primary Sjogren's syndrome. *Ann Rheum Dis*. 2011;70:505.

[136] Seror R, Theander E, Bootsma H, Bowman SJ, Tzioufas A, Gottenberg JE, Ramos-Casals M, Dörner T, Ravaut P, Mariette X, Vitali C. Outcome measures for primary Sjögren's syndrome: a comprehensive review. *J Autoimmun*. 2014;51:51-6.

[137] Risselada AP, Kruize AA, Goldschmeding R, Lafeber FP, Bijlsma JW, van Roon JA. The prognostic value of routinely performed minor salivary gland assessments in primary Sjögren's syndrome. *Ann Rheum Dis*. 2014 Aug;73:1537-40.

- [138] Theander E, Vasaitis L, Baecklund E, Nordmark G, Warfvinge G, Liedholm R, Brokstad K, Jonsson R, Jonsson MV. Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjogren's syndrome. *Ann Rheum Dis.* 2011;70:1363-8.
- [139] De Vita S, De Marchi G, Sacco S, Gremese E, Fabris M, Ferraccioli G. Preliminary classification of nonmalignant B cell proliferation in Sjogren's syndrome: perspectives on pathobiology and treatment based on an integrated clinico-pathologic and molecular study approach. *Blood Cells Mol Dis.* 2001;27:757-66.
- [140] Pijpe J, Kalk WW, Bootsma H, Spijkervet FK, Kallenberg CG, Vissink A. Progression of salivary gland dysfunction in patients with Sjögren's syndrome. *Ann Rheum Dis.* 2007;66:107–12.
- [141] Meijer JM, Meiners PM, Vissink A, Spijkervet FK, Abdulahad W, Kamminga N, et al. Effectiveness of rituximab treatment in primary Sjögren's syndrome a randomized, double-blind, placebo-controlled trial. *Arthritis Rheum.* 2010;62:960-8.
- [142] Voulgarelis M, Ziakas PD, Papageorgiou A, Baimpa E, Tzioufas AG, Moutsopoulos HM. Prognosis and outcome of non-Hodgkin lymphoma in primary Sjogren syndrome. *Medicine (Baltimore).* 2012;91:1-9.
- [143] Theander E, Manthorpe R, Jacobsson LT. Mortality and causes of death in primary Sjogren's syndrome: a prospective cohort study. *Arthritis Rheum.* 2004;50:1262-9.
- [144] Skopouli FN, Dafni U, Ioannidis JP, Moutsopoulos HM. Clinical evolution, and morbidity and mortality of primary Sjogren's syndrome. *Semin Arthritis Rheum.* 2000;29:296-304.
- [145] Ioannidis JP, Vassiliou VA, Moutsopoulos HM. Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjogren's syndrome. *Arthritis Rheum.* 2002;46:741-7.
- [146] Quartuccio L, Isola M, Baldini C, Priori R, Bartoloni Bocci E, Carubbi F, Maset M, Gregoraci G, Della Mea V, Salvin S, De Marchi G, Luciano N, Colafrancesco S, Alunno A, Giacomelli R, Gerli R, Valesini G, Bombardieri S, De Vita S. Biomarkers of lymphoma in Sjogren's syndrome and evaluation of the lymphoma risk in prelymphomatous conditions: results of a multicenter study. *J Autoimmun.* 2014;51:75-80.

- [147] Theander E, Henriksson G, Ljungberg O, Mandl T, Manthorpe R, Jacobsson LT. Lymphoma and other malignancies in primary Sjogren's syndrome: a cohort study on cancer incidence and lymphoma predictors. *Ann Rheum Dis*. 2006;65:796-803.
- [148] Tzioufas AG, Boumba DS, Skopouli FN, Moutsopoulos HM. Mixed monoclonal cryoglobulinemia and monoclonal rheumatoid factor cross-reactive idiotypes as predictive factors for the development of lymphoma in primary Sjogren's syndrome. *Arthritis Rheum*. 1996;39:767-72.
- [149] De Re V, De Vita S, Sansonno D, Toffoli G. Mixed cryoglobulinemia syndrome as an additional autoimmune disorder associated with risk for lymphoma development. *Blood*. 2008;111(12):5760.
- [150] Brito-Zeron P, Ramos-Casals M, Bove A, Sentis J, Font J. Predicting adverse outcomes in primary Sjogren's syndrome: identification of prognostic factors. *Rheumatology (Oxford)*. 2007;46:1359-62.
- [151] Voulgarelis M, Dafni UG, Isenberg DA, Moutsopoulos HM. Malignant lymphoma in primary Sjogren's syndrome: a multicenter, retrospective, clinical study by the European Concerted Action on Sjogren's Syndrome. *Arthritis Rheum*. 1999;42:1765-72.
- [152] Ramos-Casals M, Brito-Zerón P, Yagüe J, Akasbi M, Bautista R, Ruano M, Claver G, Gil V, Font J. Hypocomplementaemia as an immunological marker of morbidity and mortality in patients with primary Sjogren's syndrome. *Rheumatology (Oxford)*. 2005;44(1):89-94.
- [153] Baimpa E, Dahabreh IJ, Voulgarelis M, Moutsopoulos HM. Hematologic manifestations and predictors of lymphoma development in primary Sjogren syndrome: clinical and pathophysiologic aspects. *Medicine (Baltimore)*. 2009;88:284-93.
- [154] Solans-Laque R, Lopez-Hernandez A, Bosch-Gil JA, Palacios A, Campillo M, Vilardell-Tarres M. Risk, predictors, and clinical characteristics of lymphoma development in primary Sjogren's syndrome. *Semin Arthritis Rheum*. 2011;41:415-23.
- [155] Quartuccio L, Baldini C, Bartoloni E, Priori R, Carubbi F, Corazza L, Corazza L, Alunno A, Colafrancesco S, Luciano N, Giacomelli R, Gerli R, Valesini G, Bombardieri S, De Vita S. Anti-SSA/SSB-negative Sjogren's syndrome shows a lower prevalence of lymphoproliferative manifestations, and a lower risk of lymphoma evolution. *Autoimmun Rev*. 2015;14:1019-22.

- [156] Kruize AA, Hené RJ, Kallenberg CG, van Bijsterveld OP, van der Heide A, Kater L, et al. Hydroxychloroquine treatment for primary Sjögren's syndrome: a two year double blind crossover trial. *Ann Rheum Dis*. 1993 May;52(5):360-4.
- [157] Fox RI, Dixon R, Guarrasi V, Hené RJ, Kallenberg CG, van Bijsterveld OP, van der Heide A, Kater L, Bijlsma JW.. Treatment of primary Sjögren's syndrome with hydroxychloroquine: a retrospective, open-label study. *Lupus* 1996;5(Suppl 1):S31-6.
- [158] Gottenberg JE, Ravaud P, Puéchal X, Le Guern V, Sibilia J, Goeb V, Larroche C, Dubost JJ, Rist S, Saraux A, Devauchelle-Pensec V, Morel J, Hayem G, Hatron P, Perdriger A, Sene D, Zarnitsky C, Batouche D, Furlan V, Benessiano J, Perrodeau E, Seror R, Mariette X. Effects of hydroxychloroquine on symptomatic improvement in primary Sjögren syndrome: the JOQUER randomized clinical trial. *JAMA*. 2014;312:249-58.
- [159]. Skopouli FN, Jagiello P, Tsifetaki N, Moutsopoulos HM Methotrexate in primary Sjögren's syndrome. *Clin Exp Rheumatol*. 1996;14:555-8.
- [160] Price EJ, Rigby SP, Clancy U, Venables PJ. A double blind placebo controlled trial of azathioprine in the treatment of primary Sjögren's syndrome. *J Rheumatol*. 1998;25:896-9.
- [161] Willeke P, Schlüter B, Becker H, Schotte H, Domschke W, Gaubitz M. Mycophenolate sodium treatment in patients with primary Sjögren syndrome: a pilot trial. *Arthritis Res Ther*. 2007;9:R115.
- [162] Ramos-Casals M, Brito-Zeron P, Siso-Almirall A, Bosch X, Tzioufas AG. Topical and systemic medications for the treatment of primary Sjögren's syndrome. *Nat Rev Rheumatol* 2012;8:399-411.
- [163] Mavragani CP, Moutsopoulos NM, Moutsopoulos HM.. The management of Sjögren's syndrome. *Nat Clin Pract Rheumatol* 2006;2:252-61.
- [164] Ramos-Casals M, Tzioufas AG, Stone JH, Sisó A, Bosch X. Treatment of primary Sjögren syndrome: a systematic review. *JAMA* 2010;304:452-60.
- [165] Devauchelle-Pensec V, Mariette X, Jousse-Joulin S, Berthelot JM, Perdriger A, Puéchal X, Le Guern V, Sibilia J, Gottenberg JE, Chiche L, Hachulla E, Hatron PY, Goeb V, Hayem G, Morel J, Zarnitsky C, Dubost JJ, Pers JO, Nowak E, Saraux A. Treatment of primary Sjögren syndrome with rituximab: a randomized trial. *Ann Intern Med*. 2014 Feb 18;160:233-42.

- [166] Bowman S, Everett C, Bombardieri M, Busch R, Emery P, Hall F, et al. Preliminary results of a double-blind randomized trial of rituximab anti-B-cell therapy in patients with primary Sjogrens Syndrome (abstract). *Arthritis Rheumatol.* 2015; 67(suppl 10).
- [167]. De Vita S, Quartuccio L, Seror R, Salvin S, Ravaud P, Fabris M, Nocturne G, Gandolfo S, Isola M, Mariette X. Efficacy and safety of belimumab given for 12 months in primary Sjogren's syndrome: the BELISS open-label phase II study. *Rheumatology (Oxford).* 2015;54:2249-56.
- [168] Mariette X, Seror R, Quartuccio L, Baron G, Salvin S, Fabris M, Desmoulin F, Nocturne G, Ravaud P, De Vita S. Efficacy and safety of belimumab in primary Sjogren's syndrome: results of the BELISS open-label phase II study. *Ann Rheum Dis.* 2015;74:526-31.
- [169] Adler S, Körner M, Förger F, Huscher D, Caversaccio MD, Villiger PM. Evaluation of histologic, serologic, and clinical changes in response to abatacept treatment of primary Sjögren's syndrome: a pilot study. *Arthritis Care Res (Hoboken).* 2013;65:1862-8.
- [170] Meiners PM, Vissink A, Kroese FG, Spijkervet FK, Smitt-Kamminga NS, Abdulahad WH, et al. Abatacept treatment reduces disease activity in early primary Sjögren's syndrome (open-label proof of concept ASAP study). *Ann Rheum Dis.* 2014;73:1393-6.
- [171] De Vita S, Quartuccio L, Isola M, Mazzaro C, Scaini P, Lenzi M, Campanini M, Naclerio C, Tavoni A, Pietrogrande M, Ferri C, Mascia MT, Masolini P, Zabotti A, Maset M, Roccatello D, Zignego AL, Pioltelli P, Gabrielli A, Filippini D, Perrella O, Migliaresi S, Galli M, Bombardieri S, Monti G.. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. *Arthritis Rheum.* 2012;64:843-53.
- [172] Gottenberg JE, Cinquetti G, Larroche C, Combe B, Hachulla E, Meyer O, Pertuiset E, Kaplanski G, Chiche L, Berthelot JM, Gombert B, Goupille P, Marcelli C, Feuillet S, Leone J, Sibia J, Zarnitsky C, Carli P, Rist S, Gaudin P, Salliot C, Piperno M, Deplas A, Breban M, Lequerre T, Richette P, Ghiringhelli C, Hamidou M, Ravaud P, Mariette X; Club Rhumatismes et Inflammations and the French Society of Rheumatology. Efficacy of rituximab in systemic manifestations of primary Sjogren's syndrome: results in 78 patients of the AutoImmune and Rituximab registry. *Ann Rheum Dis.* 2013;72:1026-31.
- [173] De Vita S, Quartuccio L, Salvin S, Picco L, Scott CA, Rupolo M, Fabris M. Sequential therapy with belimumab followed by rituximab in Sjogren's syndrome associated with B-cell

lymphoproliferation and overexpression of BAFF: evidence for long-term efficacy. *Clin Exp Rheumatol.* 2014;32:490-4.

[174] Quartuccio L, Salvin S, Corazza L, Gandolfo S, Fabris M, De Vita S. Efficacy of belimumab and targeting of rheumatoid factor-positive B-cell expansion in Sjögren's syndrome: follow-up after the end of the phase II open-label BELISS study. *Clin Exp Rheumatol.* 2016;34:311-4.

[175] Winthrop KL, Strand V, van der Heijde DM, Mease PJ, Crow MK, Weinblatt M, Bathon JM, Buch MH, Burmester GR, Dougados M, Kay J, Mariette X, Breedveld FC, Kalden JR, Smolen JS, Furst DE. The unmet need in rheumatology: reports from the Targeted Therapies meeting 2016. *Clin Exp Rheumatol.* 2016;34:69-76

[176] Klabunde CN, Potosky AL, Legler JM, Warren JL. Development of a comorbidity index using physician claims data. *J Clin Epidemiol* 2000;53:1258-67

[177] Ruscitti P, Cipriani P, Di Benedetto P, Ciccia F, Liakouli V, Carubbi F, Berardicurti O, Rizzo A, Triolo G, Giacomelli R. Increased level of H-ferritin and its imbalance with L-ferritin, in bone marrow and liver of patients with adult onset Still's disease, developing macrophage activation syndrome, correlate with the severity of the disease. *Autoimmun Rev.* 2015;14:429-37.

[178] Cipriani P, Di Benedetto P, Ruscitti P, Capece D, Zazzeroni F, Liakouli V, Pantano I, Berardicurti O, Carubbi F, Pecetti G, Turrinchia S, Alesse E, Iglarz M, Giacomelli R. The Endothelial-mesenchymal Transition in Systemic Sclerosis Is Induced by Endothelin-1 and Transforming Growth Factor- β and May Be Blocked by Macitentan, a Dual Endothelin-1 Receptor Antagonist. *J Rheumatol.* 2015 Oct;42(10):1808-16. doi: 10.3899/jrheum.150088. Epub 2015 Aug 15.

[179] Cipriani P, Di Benedetto P, Capece D, Zazzeroni F, Liakouli V, Ruscitti P, Pantano I, Berardicurti O, Carubbi F, Alesse E, Giacomelli R. Impaired Cav-1 expression in SSc mesenchymal cells upregulates VEGF signaling: a link between vascular involvement and fibrosis. *Fibrogenesis Tissue Repair.* 2014;7:13.

[180] Giacomelli R, Gorla R, Trotta F, Tirri R, Grassi W, Bazzichi L, Galeazzi M, Matucci-Cerinic M, Scarpa R, Cantini F, Gerli R, Lapadula G, Sinigaglia L, Ferraccioli G, Olivieri I, Ruscitti P, Sarzi-Puttini P. Quality of life and unmet needs in patients with inflammatory arthropathies: results from the multicentre, observational RAPSODIA study. *Rheumatology (Oxford).* 2015;54:792-7.

[181] Espitia-Thibault A, Masseur A, Néel A, Espitia O, Toquet C, Mussini JM, Hamidou M.

Sjögren's syndrome-associated myositis with germinal centre-like structures. *Autoimmun Rev.* 2017;16:154-158.

[182] Chang C. Unmet needs in the treatment of autoimmunity: from aspirin to stem cells. *Autoimmun Rev.* 2014;13:331-46.

[183] Bosques CJ, Manning AM. Fc-gamma receptors: Attractive targets for autoimmune drug discovery searching for intelligent therapeutic designs. *Autoimmun Rev.* 2016;15:1081-1088.

[184] Elshabrawy HA, Essani AE, Szekanecz Z, Fox DA, Shahrara S. TLRs, future potential therapeutic targets for RA. *Autoimmun Rev.* 2017;16:103-113

[185] Leone A, Radin M, Almarzooqi AM, AlSaleh J, Roccatello D, Sciascia S, Khamashta M. Autologous Hematopoietic Stem Cell Transplantation in Systemic Lupus Erythematosus and Antiphospholipid Syndrome: A systematic review. *Autoimmun Rev.* 2017 Mar 6. pii: S1568-9972(17)30061-7. doi: 10.1016/j.autrev.2017.03.008. [Epub ahead of print].

[186] Misra DP, Sharma A, Kadiravan T, Negi VS. A scoping review of the use of non-biologic disease modifying anti-rheumatic drugs in the management of large vessel vasculitis. *Autoimmun Rev.* 2017;16:179-191.

[187] Ruscitti P, Cipriani P, Di Benedetto P, Liakouli V, Berardicurti O, Carubbi F, Ciccina F, Alvaro S, Triolo G, Giacomelli R. Monocytes from patients with rheumatoid arthritis and type 2 diabetes mellitus display an increased production of interleukin (IL)-1 β via the nucleotide-binding domain and leucine-rich repeat containing family pyrin 3(NLRP3)-inflammasome activation: a possible implication for therapeutic decision in these patients. *Clin Exp Immunol.* 2015;182:35-44.

[188] Houry Levi E, Watad A, Whitby A, Tiosano S, Comaneshter D, Cohen AD, Amital H. Coexistence of ischemic heart disease and rheumatoid arthritis patients-A case control study. *Autoimmun Rev.* 2016;15:393-6

[189] Ruscitti P, Cipriani P, Masedu F, Iacono D, Ciccina F, Liakouli V, Guggino G, Carubbi F, Berardicurti O, Di Benedetto P, Valenti M, Triolo G, Valentini G, Giacomelli R. Adult-onset Still's disease: evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three centers. *BMC Med.* 2016;14:19

[190] Ruscitti P, Cipriani P, Ciccina F, Masedu F, Liakouli V, Carubbi F, Berardicurti O, Guggino G, Di Benedetto P, Di Bartolomeo S, Valenti M, Triolo G, Giacomelli R. Prognostic factors of

macrophage activation syndrome, at the time of diagnosis, in adult patients affected by autoimmune disease: Analysis of 41 cases collected in 2 rheumatologic centers. *Autoimmun Rev.* 2017;16:16-21.

[191] Tektonidou MG, Kravvariti E, Konstantonis G, Tentolouris N, Sfikakis PP, Protogerou A. Subclinical atherosclerosis in Systemic Lupus Erythematosus: Comparable risk with Diabetes Mellitus and Rheumatoid Arthritis. *Autoimmun Rev.* 2017;16:308-312.

[192] López-Mejías R, Castañeda S, González-Juanatey C, Corrales A, Ferraz-Amaro I, Genre F, Remuzgo-Martínez S, Rodríguez-Rodríguez L, Blanco R, Llorca J, Martín J, González-Gay MA. Cardiovascular risk assessment in patients with rheumatoid arthritis: The relevance of clinical, genetic and serological markers. *Autoimmun Rev.* 2016;15:1013-1030.

Novel risk factors related to cancer in scleroderma.

[193] Bernal-Bello D, de Tena JG, Guillén-Del Castillo A, Selva-O'Callaghan A, Callejas-Moraga EL, Marín-Sánchez AM, Fonollosa-Pla V, Simeón-Aznar CP. Novel risk factors related to cancer in scleroderma.. *Autoimmun Rev.* 2017 Mar 8

[194] Islam MA, Alam F, Wong KK. Comorbid association of antiphospholipid antibodies and migraine: A systematic review and meta-analysis. *Autoimmun Rev.* 2017 Mar 7. pii: S1568-9972(17)30058-7. doi: 10.1016/j.autrev.2017.03.005. [Epub ahead of print]

[195] Martínez AR, Faber I, Nucci A, Appenzeller S, França MC Jr. Autoimmune neuropathies associated to rheumatic diseases. *Autoimmun Rev.* 2017; Apr;16(4):335-342Apr;16(4):335-342

[196] Becker NP, Müller J, Göttel P, Wallukat G, Schimke I. Cardiomyopathy - An approach to the autoimmune background. *Autoimmun Rev.* 2017;16:269-286

[197] Ruscitti P, Cipriani P, Masedu F, Romano S, Berardicurti O, Liakouli V, Carubbi F, Di Benedetto P, Alvaro S, Penco M, Valenti M, Giacomelli R. Increased Cardiovascular Events and Subclinical Atherosclerosis in Rheumatoid Arthritis Patients: 1 Year Prospective Single Centre Study. *PLoS One.* 2017 Jan 19;12(1):e0170108

[198] Loza E, Lajas C, Andreu JL, Balsa A, González-Álvaro I, Illera O, Jover JÁ, Mateo I, Orte J, Rivera J, Rodríguez Heredia JM, Romero F, Martínez-López JA, Ortiz AM, Toledano E, Villaverde V, Carmona L, Castañeda S. Consensus statement on a framework for the management of comorbidity and extra-articular manifestations in rheumatoid arthritis. *Rheumatol Int.* 2015;35:445-

58.

Statements	LoE	GoR
<i>Rheumatoid Arthritis Working Group</i>		
Based on direct and indirect comparative studies, no significant differences according to ACR response criteria, functional status, and radiographic progression exist among available biological drugs combined with MTX in both MTX-naïve and MTX-insufficient responder patients.	1a	A
The kinetics of response of subcutaneous abatacept and adalimumab are comparable.	1b	A
No significant differences in time to response among other biological drugs may be assessed.	5	D
Based on data coming from main international registries, the long-term drug persistence of etanercept seems to be higher when compared with monoclonal antibodies (adalimumab and infliximab).	2b	B
No significant differences in long-term drug retention among other biological drugs may be assessed.	5	D
Tocilizumab as monotherapy can be used with a similar efficacy to combination therapy for patients intolerant to MTX.	1b	A
Tocilizumab monotherapy demonstrated superiority over adalimumab monotherapy in reducing signs and symptoms of RA in MTX-intolerant patients, or in whom MTX was considered ineffective or inappropriate. No comparative data against tocilizumab are available for others TNF inhibitors.	1b	A
Although a worsening of interstitial lung disease has been reported in RA patients treated with biologic drugs, the role of biological therapy is still unclear.	5	D

Golimumab, infliximab, and especially tocilizumab have been proven to significantly improve anemia, whereas no data are available for other biologic drugs.	1b	B
Vasculitis may be effectively treated with rituximab, whereas no data are available for other biologics. Data from the literature do not show consistent evidence of possible therapeutic effects of biologics on other extra-articular manifestations of RA.	4	C
In RA patients treated with biologic agents, a possible strategy for maintaining clinical remission and/or low disease activity could be the dose tapering or increasing administration intervals.	1b	A
Data on genetic, serological, and synovial biomarkers are still controversial and not useful to personalize RA treatment.	5	D
The positivity of RF and/or ACPA could be useful to drive the choice to rituximab.	2	C
<i>Spondyloarthritides Working Group</i>		
Continuous NSAIDs treatment might be efficacy on slowing radiographic progression in the spine of AS patients.	1a	A
Continuous NSAIDs treatment seems to be not efficacy on slowing radiographic progression in the spine of nrAxSpA.	3b	B
Sulfasalazine might be efficacy in slowing sacroiliac radiographic progression in patients with nrAxSpA but not in AS.	2b	B
TNFi might be efficacy in slowing radiographic progression in patients with AS.	3b	B
TNFi might be efficacy in slowing radiographic progression in patients with nrAxSpA.	3b	B
TNFi showed efficacy in reducing disease activity in both AS and nrAxSpA, without significant differences between the different molecules.	1a	A
Infliximab biosimilar is equivalent to infliximab in terms of efficacy. No data are available on slowing disease progression.	1b	A

ESR, CRP, ASDAS and male gender are independent baseline predictors of response and/or continuation of TNFi.	2b	B
Discontinuation of pharmacologic treatments might be tried in AS patients but high frequency of relapse is predictable (50% in 6 months, 70 % in 1 year, 100% in 3 years).	2b	B
A tailored approach to reduce doses of TNFi seems to produce similar clinical outcomes at 1 year in AS patients.	3b	B
<i>Systemic sclerosis working group</i>		
HSCT has been found to prolong survival in one controlled study. Mycophenolate has been reported to prolong survival in a retrospective cohort study.	2	B
No drug has been consistently found to prevent or treat myocardial fibrosis.	4	C
Mycophenolate, rituximab and imatinib have been reported to be effective in SSc-ILD unresponsive to cyclophosphamide in prospective uncontrolled studies.	3	C
The proposed treatments for gut fibrosis have only a symptomatic effect.	3	C
MTX and biological drugs have been found to be effective on arthritis in uncontrolled studies.	3	D
No drug or therapy has been consistently found to affect disfiguring skin disease	5	D
<i>Systemic lupus erythematosus working group</i>		
Rituximab can be used in refractory lupus nephritis.	2	B
Rituximab and abatacept can be used in refractory arthritis.	3	C
TNFi can be used in refractory arthritis only for a short period of time.	3	C
Rituximab can be used in refractory hemolytic anemia, thrombocytopenia, mucocutaneous and neuropsychiatric lupus manifestations.	3	C

To date there are no sufficient data to support the use of other biologics.	5	D
Biologics can be used as steroid sparing agents: belimumab and rituximab.	1b/3	A/C
<i>Antiphospholipid syndrome working group</i>		
Women who presented at least two miscarriages and persistent LA positivity alone should be considered for treatment.	4	D
Women who experienced two miscarriages and have Sydney laboratory criteria should be considered for treatment.	1b	B
Women with low-titre anti-cardiolipin/anti-beta2GPI and clinical Sydney clinical criteria should be considered for treatment.	2b	B
It could be useful to adopt an “add-on” strategy (HCQ, corticosteroids, IVIG, apheresis) in refractory or high-risk (previous thrombosis, previous early severe pregnancy complications) cases of obstetric APS.	2a	C
It could be useful to perform a stronger anticoagulation in APS patients who experienced arterial thrombosis recurrences.	4	D
Medium-high titres and/or triple positive aPL carriers should be considered for treatment with LDA or also with HCQ in case of concomitant autoimmune diseases (such as SLE).	3	C
<i>Sjogren’s syndrome working group</i>		
ACR-EULAR new classification criteria have been developed and validated showing a very good performance in terms of sensitivity and specificity, and a high level of agreement with previously proposed criteria, mainly with AECG criteria.	1b	A
The new criteria should represent the gold standard for classification of patients to be enrolled in future studies. Additional criteria of selection can be allowed to select particular subsets of patients for specific studies.	5	D

The use of ESSDAI in real-life provides a reliable picture of systemic involvement in SS patients. Measurement of baseline systemic activity by ESSDAI is significantly associated with the prognosis.	2b	B
The ESSDAI, ESSPRI, patient global assessment and the quality of life should be all evaluated, since they are complementary to assess the disease and since the correlation between them is low.	2b	B
The histological assessment and the measurement of salivary flow should be included in SS trials.	5	D
Clinical (persistent parotid swelling, purpura), hematological (low C4, cryoglobulinemia, leukopenia), and histological (germinal center-like structures) features are still insufficient as biomarkers of SS. Autoantibody formation and hypergammaglobulinemia are associated with extra-glandular manifestations.	3b	C
Traditional and new clinical and laboratory biomarkers are needed to improve the diagnosis of SS, to categorize subsets of patients, and to unmask pathogenic mechanisms which may represent novel therapeutic targets.	5	D
DMARDs are given for systemic involvement; their administration is based on non-controlled studies and expert opinion. HCQ and MTX are effective for arthritis, cyclophosphamide for severe vasculitis, small doses/short courses corticosteroids for constitutional symptoms, parotid gland enlargement and arthritis.	5	D
Biologics may represent an effective treatment for SS in the future; B-cell depletion appears now recommended mainly for systemic manifestations and for persistent parotid swelling; residual glandular function is a prerequisite to enrol patients in trials to study sicca.	4	D
Larger multicentre, double blind studies, with the study of histology and biomarkers, are needed, applied in phenotypically homogeneous SS populations to be better stratified.	5	D

ACCEPTED MANUSCRIPT